Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the year ended December 31, 2020
For the transition period from to
Commission file number 001-38804
ZYNEX, INC.
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of
incorporation or organization)
9555 Maroon Circle, Englewood, CO
(Address of principal executive offices)
90-0275169
(IRS Employer
Identification No.)
80112
(Zip Code)
Securities registered pursuant to Section 12(b) of the Act:
Registrant’s telephone number, including area code: (303) 703-4906
Title of each class
Common Stock, $0.001 par value per share
Ticker symbol(s)
ZYXI
Name of each exchange on which registered
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
Title of each class
Common Stock, $0.001 par value
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ⌧ No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ☐ Yes ⌧ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. ⌧ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ⌧ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange
Act.
Large accelerated filer
Non-accelerated filer
☐ Accelerated filer
⌧
Smaller reporting company
Emerging growth company
☐
☒
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant as of June 30, 2020, the last business day of the Registrant’s last
completed second quarter, based upon the closing price of the common stock as reported by the Nasdaq Stock Market on such date was approximately $422.4 million.
As of February 25, 2021, 36,135,103 shares of common stock are issued and 34,849,482 shares are outstanding.
Documents incorporated by reference:
Portions of the Registrant’s definitive proxy statement relating to its 2021 annual meeting of shareholders (the “ Proxy Statement”) are incorporated by reference into Part
III of this Annual Report on Form 10-K where indicated. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the
end of the fiscal year to which this report relates.
Table of Contents
TABLE OF CONTENTS
ZYNEX, INC
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2020
PART I
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
PART II
Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6. Selected Financial Data
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures
Item 9A. Controls and Procedures
Item 9B. Other Information
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accounting Fees and Services
PART IV
Item 15. Exhibits, Financial Statement Schedules
Signatures
Page
2
2
9
17
17
17
17
17
17
18
18
25
25
25
26
26
26
26
27
27
27
27
28
28
31
Table of Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This report includes statements of our expectations, intentions, plans, and beliefs that constitute “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Nonetheless, it is important for an investor to understand that these statements involve risks and uncertainties. These
statements relate to the discussion of our business strategies and our expectations concerning future operations, margins, profitability,
liquidity, and capital resources and to analyses and other information that are based on forecasts of future results and estimates of
amounts not yet determinable. We have used words such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,”
“think,” “estimate,” “seek,” “expect,” “predict,” “could,” “project,” “potential,” and other similar terms and phrases, including references
to assumptions, in this report to identify forward-looking statements. These forward-looking statements are made based on expectations
and beliefs concerning future events affecting us and are subject to uncertainties, risks and factors relating to our operations and business
environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ
materially from those matters expressed or implied by these forward-looking statements.
Such risks and other factors also include those listed in Item 1A. “Risk Factors and elsewhere in this report and our other filings with the
Securities and Exchange Commission. When considering these forward-looking statements, you should keep in mind the cautionary
statements in this report and the documents incorporated by reference. New risks and uncertainties arise from time to time, and we
cannot predict those events or how they may affect us. We assume no obligation to update any forward-looking statements after the date
of this report as a result of new information, future events or developments, except as required by applicable laws and regulations.
When used in this annual report, the terms the “Company,” “Zynex”, “we,” “us,” “ours,” and similar terms refer to Zynex, Inc., a Nevada
corporation, and its subsidiaries, Zynex Medical, Inc., Zynex NeuroDiagnostics, Inc., Zynex Monitoring Solutions Inc., Zynex Europe
ApS and Pharmazy, Inc. As of the date of this annual report, our only operating subsidiary is Zynex Medical, Inc. (“ZMI”). Zynex
Monitoring Solutions, Inc. (“ZMS”) has developed its blood volume monitoring product as described below.
1
Table of Contents
ITEM 1. BUSINESS
History
PART I
Zynex, Inc. was founded by Thomas Sandgaard in 1996, when he founded two privately held companies that eventually were folded into
Zynex, Inc. Zynex, Inc., a Nevada corporation is the parent company of and conducts business within five subsidiaries: Zynex Medical,
Inc. (“ZMI”), a Colorado corporation, Zynex NeuroDiagnostics, Inc. (“ZND”), a Colorado corporation, Zynex Monitoring Solutions, Inc.
(“ZMS”), a Colorado corporation, Zynex Europe (Zynex Europe ApS) (“ZEU”), a Danish corporation, and Pharmazy, Inc. (“Pharmazy”),
which was incorporated under the laws of Colorado in June 2015 as a wholly-owned subsidiary of ZMI (Zynex, Inc. collectively with the
foregoing subsidiaries may be referred to as “Zynex” or the “Company”).
As of December 31, 2020, the Company conducts most of its operations through its primary subsidiary, ZMI. ZMS has developed a
blood volume monitoring device which was granted 510(K) clearance in February 2020 by the Food and Drug Administration (“FDA”)
in the United States of America and is in the process of receiving CE Marking in Europe. In addition, in January 2021 ZMS filed for a
provisional patent for a non-invasive sepsis monitor. ZMS has achieved no revenues to date. Our inactive subsidiaries include ZND and
Pharmazy. The Company’s compounding pharmacy operated as a division of ZMI dba as Pharmazy through January 2016. The Company
also dissolved its subsidiary Zynex Billing and Consulting, LLC (ZBC) as a result of its long-standing inactivity. Upon dissolution, the
Company eliminated its non-controlling interest in ZBC.
Substantially all of our consolidated revenue in 2020 and 2019 is attributable to ZMI. Our headquarters are located in Englewood,
Colorado.
Active Subsidiaries
Zynex Medical, Inc. (ZMI): ZMI designs, manufactures, and markets medical devices designed to treat chronic and acute pain, as well as
activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMI devices are intended for pain management to
reduce reliance on medications and are designed to provide rehabilitation and increased mobility through the utilization of non-invasive
muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”), and
transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are intended to be patient-friendly and designed for home
use. The ZMI devices are small, portable, battery operated, and include an electrical pulse generator that is connected to the body via
electrodes. The products are cost effective when compared to traditional physical therapy, and often result in better mobility, less pain,
and increased potential for a patient to return to work earlier than with traditional therapies alone. All of our medical devices are
marketed in the U.S. and follow FDA regulations and clearance. Our products require a physician’s prescription before they can be
dispensed in the U.S. We consider the physician’s prescription as an “order”, and it is on this basis that we provide the product to the
patient and either bill the patient directly or the patient’s private or government insurer for payment. ZMI’s primary product is the
NexWave® device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires
consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring basis, as needed.
ZMI distributes complimentary products such as lumbar support, cervical traction, and hot/cold therapy. These complement our pain
management products and are critical for physicians and therapists. These products require a prescription and are covered by most
insurance plans and Medicare.
ZMI designs, manufactures, and markets the NeuroMove product. The NeuroMove contains electromyography and electric stimulation
technology that is primarily used for stroke, spinal cord and traumatic brain injury rehabilitation (“SCI”), by reaching parts of the brain to
re-connect with muscles, also known as neuroplasticity. The NeuroMove product is primarily marketed to medical clinics. Zynex did not
have material sales of this product in 2020 or 2019.
ZMI also designs, manufactures, and markets the InWave product, an in-home electrical stimulation device used to treat female urinary
incontinence. The device requires a prescription and is covered by most insurance plans and Medicare. Zynex did not have material sales
of this product in 2020 or 2019.
2
Table of Contents
Zynex Monitoring Solutions (ZMS):
ZMS was formed in 2011 to develop and market medical devices for non-invasive cardiac monitoring. The blood volume monitor is a
non-invasive medical device for monitoring central blood volume that would be used in operating and recovery rooms to detect blood
loss during surgery and internal bleeding during recovery. This device has been subjected to multiple clinical studies, which are being
utilized for collecting data to further validate the algorithm used to determine changes in central blood volume. There are plans to
conduct future, additional clinical studies. We received 510(k) clearance from the FDA in February 2020.
In addition to FDA clearance, we are pursuing European Union (“EU”) Certificate European (“CE”) Marking. CE Marking is a
certification that a product meets the standards established by the 28 nations of the EU and qualifies for sale in the EU and 4-nation
European Free Trade Association.
The blood volume monitor has been tested in several International Review Board (“IRB”) approved studies and was used in several
blood donation settings where hundreds of subjects have donated half a liter of blood with strong correlation to the index on the device.
We have built a number of commercial devices in pilot-production and continue to refine the algorithms for the Blood Volume Index
(BVI). We have received two U.S. utility patents for this unique application, the first in the fourth quarter of 2018 and the second in
January 2021, and we believe this product could serve a currently unmet need in the market for safer surgeries and safer monitoring of
patients during recovery. As ZMS’ products are still in development, ZMS did not produce any revenue for the years ending December,
31, 2020 and 2019.
In addition to the blood volume monitor, ZMS filed for a provisional patent for a non-invasive sepsis monitor in January 2021.
Zynex International (Zynex Europe) (ZEU):
ZEU was formed in 2012 to further progress Zynex’s international expansion. ZEU is currently conducting business and focused on sales
and marketing our products within the international marketplace, upon receipt of necessary regulatory approvals. ZEU did not produce
significant revenue for the years ended December 31, 2020 and 2019.
SALES AND GROWTH STRATEGIES
To date, ZMI accounts for substantially all of our revenue and profit. We are focused on expanding our sales force to address what we
believe is an untapped market for electrotherapy products which has become more attractive due to large competitors exiting the market.
As of December 31, 2020, we had approximately 500 field sales representatives on staff or in the hiring process, of which 11 were
independent, contract representatives and the rest were W-2 direct employees. We continue to hire field sales representatives at a rapid
rate with the goal of having 600 sales representatives in the U.S. by the end of 2021.
In an effort to increase revenue and diversification in order to become less sensitive to reimbursement changes, we are continually adding
new complimentary products to our ZMI sales channel, such as our hot/cold therapy, cervical traction and LSO back braces. In addition,
in March 2020 we introduced a full catalog of over 3,300 physical therapy products to promote in the clinics which we serve. These
complimentary products may offset any impact on revenue due to changes in insurance reimbursement rates of electrotherapy devices.
We are also pursuing other opportunities, including the blood volume monitor. We believe these events and actions will serve to focus
and increase our market share in the marketplace and, in the future, grow our core business by providing our electrotherapy patients
additional non-pharmacological pain relief and complementary products to our manufactured devices.
Distribution and Revenue Streams:
Currently, substantially all of our revenue is generated through our ZMI subsidiary from our electrotherapy products.
We sell through a direct sales force in United States. Our field sales representatives are engaged to sell in predefined geographic markets
and are compensated based on fixed amounts depending on the type of product sold and insurance carrier of the patient. Currently, the
United States has been the market that we have focused on.
3
Table of Contents
A significant portion of our revenue is derived from patients with insurance plans held by commercial health insurance carriers or
government payors who pay on behalf of their insureds. The remaining portion of revenue is primarily received from workers’
compensation claims and attorneys representing injured patients, hospitals, clinics and private-pay individuals.
A large part of our revenue is recurring. Recurring revenue results primarily from the sale of surface electrodes and batteries sent to
existing patients with our units. Electrodes and batteries are consumable items that are considered an integral part of our products.
Private Labeled Distributed Products
In addition to our own products, we distribute, through our sales force, a number of private labeled supplies and complimentary products
from other domestic manufacturers. These products generally include patient consumables, such as electrodes and batteries plus cervical
traction, lumbar support and hot/cold therapy. Customarily, there are no formal contracts between vendors in the durable medical
equipment industry. Replacement products and components are easily found, either from our own products or other manufacturers, and
purchases are made by purchase order.
Products
We currently market and sell Zynex-manufactured products and distribute complimentary products and private labeled supplies for
Zynex products, as indicated below:
Product Name
Description
Zynex Medical Products
NexWave
NeuroMove
InWave
E-Wave
Dual channel, multi-modality IFC, TENS, NMES device
Electromyography (EMG) — triggered electrical stimulation device
Electrical stimulation for treatment of female urinary incontinence
NMES device
Private Labeled Supplies
Electrodes
Batteries
Distributed Complementary Products
Supplies, re-usable for delivery of electrical current to the body
Supplies, for use in electrotherapy products
Comfortrac/Saunders
Cervical traction
JetStream
Hot/cold therapy
LSO Back Braces
Lumbar support
Zynex Monitoring Solutions Products
CM-1500
Blood Volume Monitor
4
Table of Contents
Product Uses
Pain Management and Control
Standard electrotherapy is a clinically proven and medically accepted alternative to manage acute and chronic pain. Electrical stimulation
has been shown to reduce most types of local pain, such as tennis elbow, neck or lower back pain, arthritis, and others. The devices used
to accomplish this are commonly described as the TENS family of devices. Electrotherapy is not known to have any negative side
effects, a significant advantage over most pain relief medications. The benefits of electrotherapy can include: pain relief, increased blood
flow, reduced edema, prevention of venous thrombosis, increased range-of-motion, prevention of muscle disuse atrophy, and reduced
urinary incontinence.
Electrotherapy introduces an electrical current applied through surface electrodes. The electrical current “distorts” a pain signal on its
way to the central nervous system and the brain, thus reducing the pain. Additionally, by applying higher levels of electricity, muscles
contract and such contraction is believed to assist in the benefits mentioned above.
Numerous clinical studies have been published over several decades showing the effectiveness of IFC and TENS for pain relief. Our
primary electrotherapy device, the NexWave, has received FDA 510(k) clearance. The NexWave is a digital IFC, TENS and NMES
device that delivers pain-alleviating electrotherapy.
Stroke and Spinal Cord Injury Rehabilitation
Our proprietary NeuroMove product is a Class II medical device that has been cleared by the FDA for stroke and SCI rehabilitation.
Stroke and SCI usually affect a survivor’s mobility, functionality, speech, and memory, and the NeuroMove is designed to help the
survivor regain movement and functionality.
Sales of NeuroMove have not generated material revenue for the years ended December 31, 2020 and 2019.
MARKETS
Zynex Medical (ZMI):
To date, the majority of our revenue has been generated by our ZMI electrotherapy products and private label supplies. Thus, we
primarily compete in the home electrotherapy market for pain management, with products based on IFC, TENS and NMES devices and
consumable supplies. We estimate the annual domestic market for home electrotherapy products at approximately $500 million. During
2019 and 2020, we grew our sales force to approximately 500 direct sales reps to address what we believe is an underserved
electrotherapy market. The current opioid epidemic has been declared a health emergency, and we are uniquely positioned to help reduce
the amount of opioids prescribed for treatment of chronic and acute pain symptoms. We are committed to providing health care
professionals with alternatives to traditional opioid based treatment programs with our prescription-strength products which have no
side-effects. This has never been more necessary than it is today considering the staggering statistics.
● Pain impacts the lives of more Americans than diabetes, heart disease, and cancer combined.
● Pain is the leading cause of disability, and seeking treatment for chronic or acute pain is the most common reason
American’s seek health care. Approximately 50 million Americans suffer from chronic pain.
● Nearly 20 million Americans experienced high-impact chronic pain, defined as “limiting life or work activities on
most days or every day”, in the past 6 months.
● If pharmaceuticals such as opioids continue to be used as the first line of defense, America will continue to see a rise in
opioid misuse, addiction and drug-related deaths.
We also distribute complimentary products such as JetStream Hot/Cold Therapy, Aspen LSO Back bracing and Comfortrac and Saunders
cervical and lumbar traction units, all products targeted at treating acute as well as chronic pain with minimal side-effects.
5
Table of Contents
Key characteristics of our electrotherapy market are:
● Collection cycles of initial payment from insurance carriers can range from 30 days to many months and considerably
longer for many attorney, personal injury, and workers’ compensation cases. Such delayed payment impacts our cash flow
and can slow our growth or strain our liquidity. Collections are also impacted by whether effective billing submissions are
made by our billing and collections department to the third-party payors.
● Prior to payment, third-party payors often make or take significant payment adjustments or discounts. This can also lead to
denials and billing disputes with third-party payors.
● The majority of our revenue is generated by the sale of medical devices and from recurring patient supplies, specifically
from our electrotherapy products sold through ZMI. We are reliant on third-party payor reimbursement.
Zynex Monitoring Solutions (ZMS):
ZMS is focused on developing products within the non-invasive multi-parameter patient-monitoring marketplace. ZMS is currently
focusing on its blood volume monitor and recently announced sepsis monitor. We believe our products, once released into the
marketplace (of which there can be no guarantee), will compete against multiple competitors, ranging from large manufacturers with
multiple business lines to small manufacturers that offer a limited range of products. We have not yet identified competitors for these
products. ZMS has not generated any revenue.
Competition
Since we are in the market for medical electrotherapy products, we face a mixture of competitors ranging from large manufacturers with
multiple business lines to small manufacturers that offer a limited selection of products. Our principal competitors include International
Rehabilitative Sciences, Inc. d/b/a RS Medical, EMSI, and H-Wave. In addition, we face competition from providers of alternative
medical therapies, such as pharmaceutical companies.
RESOURCES
Manufacturing and Product Assembly
Our manufacturing and product assembly strategy consists of the following elements:
● Compliance with relevant legal and regulatory requirements.
● Use of contract manufacturers as needed, thereby allowing us to quickly respond to changes in volume and avoid large
capital investments for assembly and manufacturing equipment of certain product components. We believe there is a large
pool of highly qualified contract manufacturers, domestically and internationally, for the type of manufacturing assistance
needed for our manufactured devices.
● Utilization of in-house final assembly and test capabilities.
● Development of proprietary software and hardware for all products in house.
● Testing all units in a real-life, in-house environment to help ensure the highest possible quality and patient safety while
reducing the cost of warranty repairs.
We utilize contract manufacturers located in the U.S. to manufacture components for our NexWave and NeuroMove units and for some
of our other products and assemble in-house for our NexWave and NeuroMove units. We do not have long-term supply agreements with
our contract manufacturers, but we utilize purchase orders with agreed upon terms for our ongoing needs. We believe there are numerous
suppliers that can manufacture our products and provide our required raw materials. Generally, we have been able to obtain adequate
supplies of our required raw materials and components. We are always evaluating our suppliers for price, quality,
6
Table of Contents
delivery time and service. The reduction or interruption in supply, and an inability to develop alternative sources for such supply, could
adversely affect our operations.
Intellectual Property
We believe that our products contain certain proprietary software.
We have received two U.S. utility patents for our Blood Volume Monitor (2018 and 2021) and a utility patent in Europe (2020). In the
future, we may seek patents for advances to our existing products and for new products as they are developed.
Zynex is trademarked in the U.S.
We utilize non-disclosure and trade secret agreements with employees and third parties to protect our proprietary information.
GOVERNMENT REGULATION
Federal Drug Association (FDA)
All of our ZMI products are classified as Class II (Medium Risk) devices by the FDA, and clinical studies with our products are
considered to be NSR (Non-Significant Risk Studies). Our business is regulated by the FDA, and all products typically require 510(k)
market clearance before they can be put into commercial distribution. Section 510(k) of the Federal Food, Drug and Cosmetics Act, is
available in certain instances for Class II (Medium Risk) products. It requires that before introducing most Class II devices into interstate
commerce, the product must first submit information to the FDA demonstrating that the device is substantially equivalent in terms of
safety and effectiveness to a device legally marketed prior to March 1976 or to devices that have been reclassified in accordance with the
provisions of the Federal Food, Drug, and Cosmetic Act that do not require approval of a premarket approval application. When the FDA
determines that the device is substantially equivalent, the agency issues a “clearance” letter that authorizes marketing of the product. We
are also regulated by the FDA’s Good Manufacturing Practice (GMP) and Quality Systems Regulation (QSR). We believe that our
products have obtained or are good candidates for the requisite FDA clearance or are exempt from the FDA clearance process. In
November 2001, Zynex received FDA 510(k) clearance to market NeuroMove. In September 2011, Zynex received FDA 510(k)
clearance to market the NexWave, our current generation IFC, TENS and NMES device. In August 2012, Zynex received FDA 510(k)
clearance to market the InWave, our next generation muscle stimulator for treatment of female incontinence. Failure to comply with FDA
requirements could adversely affect us.
International
Zynex continues to explore opportunities to gain regulatory clearance for its devices in markets outside of the U.S.
CE marking is the medical device manufacturer's claim that a product meets the essential requirements of all relevant European Medical
Device Directives. The CE mark is a legal requirement to place a device on the market in the EU. Zynex is currently in the process of
applying for CE marking on several of its electrotherapy devices and its CM-1500 Blood Volume Monitor.
The Far East, Middle East, Eastern Europe and Latin American markets have different regulatory requirements. We comply with
applicable regulatory requirements within the markets in which we currently sell. If and when we decide to enter additional geographic
areas, we intend to comply with applicable regulatory requirements within those markets.
Zynex has received ISO13485: 2016 certification for its compliance with international standards in quality management systems for
design, development, manufacturing and distribution of medical devices. This certification is not only important as assurance that we
have the appropriate quality systems in place but is also crucial to our international expansion efforts as many countries require this
certification as part of their regulatory approval.
Government Regulation
The delivery of health care services and products has become one of the most highly regulated professional and business endeavors in the
United States. Both the federal government and individual state governments are responsible for overseeing the activities of
7
Table of Contents
individuals and businesses engaged in the delivery of health care services and products. Federal law and regulations are based primarily
upon the Medicare and Medicaid programs. Each program is financed, at least in part, with federal funds. State jurisdiction is based upon
the state’s interest in regulating the quality of health care in the state, regardless of the source of payment. Many state and local
jurisdictions impose additional legal and regulatory requirements on our business including various states and local licenses, taxes,
limitations regarding insurance claim submission and limitations on relationships with referral parties. Failure to comply with this myriad
of regulations in a particular jurisdiction may subject us to fines or other penalties, including the inability to sell our products in certain
jurisdictions.
Federal health care laws apply to us when we submit a claim to any other federally funded health care program, in addition to
requirements to meet government standards. The principal federal laws that we must abide by in these situations include:
● Those that prohibit the filing of false or improper claims for federal payment.
● Those that prohibit unlawful inducements for the referral of business reimbursable under federally funded health care
programs.
The federal government may impose criminal, civil and administrative penalties on anyone who files a false claim for reimbursement
from federally funded programs.
A federal law commonly known as the “anti-kickback law” prohibits the knowing or willful solicitation, receipt, offer or payment of any
remuneration made in return for:
● The referral of patients covered under federally-funded health care programs; or
● The purchasing, leasing, ordering, or arranging for any goods, facility, items or service reimbursable under those programs.
Research and Development
During 2020 and 2019, we incurred approximately $0.8 million and $0.6 million, respectively, of research and development expenses.
We expect our research and development expenditures will be limited throughout 2021.
HUMAN CAPITAL
As of December 31, 2020, we employed 768 full time employees of which 438 are employed as direct sales representatives in the field.
Additionally, we also engage 11 independent commission-only sales contractors.
Our employees are our most important assets and set the foundation for our ability to achieve our strategic objectives. All of our
employees contribute to our success and, in particular, our sales representatives are instrumental in our ability to reach more patients in
pain.
The success and growth of our business, depends in large part on our ability to attract, retain and develop a diverse population of talented
and high-performing employees at all levels of our organization. To succeed in a competitive labor market, we have developed
recruitment and retention strategies, objectives and measures that we focus on as part of the overall management of our business. These
strategies, objectives and measures form our human capital management framework and are advanced through the following programs,
policies and initiatives:
● Competitive pay and benefits. Our compensation programs are designed to align the compensation of our employees with
our performance and to provide the proper incentives to attract, retain, and motivate employees to achieve superior results.
8
Table of Contents
● Training and development. We invest in learning opportunities that foster a growth mindset. Our formal offerings include a
tuition reimbursement program, an e-learning program that all corporate employees have access to and in-house learning
opportunities through the Company’s Zynex Growth and Development program.
● Health and Wellness. We invest in the health and wellness of our employees by offering monthly benefits and offer
programs and support to assist our employees.
ITEM 1A. RISK FACTORS
RISKS RELATED TO OUR BUSINESS
We face risks related to health pandemics, particularly the recent outbreak of COVID-19, which could adversely affect our business
and results of operations.
Our business could be materially adversely affected by a widespread outbreak of contagious disease, including the recent outbreak of the
novel coronavirus, known as COVID-19, which has spread to many countries throughout the world, including the United States. The
effects of this outbreak on our business have included and could continue to include temporary closures of our providers and clinics and
suspensions of elective surgical procedures. This has and could continue to impact our interactions and relationships with our customers.
In addition to temporary closures of the providers and clinics that we serve, we could also experience temporary closures of the facilities
of our suppliers, contract manufacturers, or other vendors in our supply chain, which could impact our business, interactions and
relationships with our third-party suppliers and contractors, and results of operations. The extent to which the COVID-19 outbreak will
impact business and the economy is highly uncertain and cannot be predicted. Accordingly, we cannot predict the extent to which our
financial condition, results of operations and value of our common stock will be affected. The uncertainty surrounding the COVID-19
outbreak has caused the Company to increase its inventory in anticipation of possible supply chain shortages related to the COVID-19
virus. While the Company did not incur significant disruptions to its operations during 2020, it is unable at this time to predict the impact
that the COVID-19 virus will have on its business, financial position and operating results in future periods due to numerous
uncertainties.
We have encountered significant volatility in our recent operating results.
The Company’s results from operations have improved significantly in recent years, but there have been significant volatility in our
results over the past five years as reflected in the following table (in millions):
Year
2016
2017
2018
2019
2020
Revenues
Profit
$
$
$
$
$
13.3
23.4
31.9
45.5
80.1
$
$
$
$
$
0.07
7.4
9.6
9.5
9.1
Our financial results could continue to be volatile, and there is no assurance we will continue our current increase in revenue and profits.
We are dependent on reimbursement from third-party payors; changes in insurance reimbursement policies or application of them
have resulted in decreased or delayed revenues.
A large percentage of our revenues come from third-party payor reimbursement. Upon delivery of our products to our patients, we
directly bill the patients’ private insurance companies or government payors for reimbursement. If the third-party payors do not remit
payment on a timely basis or if they change their policies to exclude or reduce coverage for our products, we would experience a decline
in our revenue as well as cash flow. In addition, we may deliver products to patients and invoice based on past practices and billing
experiences only to have third-party payors later deny coverage for such products.
9
Table of Contents
In some cases, our delivered product may not be covered pursuant to a policy statement of a third-party payor, despite a payment history
with the third-party payor and benefits to the patients. A third-party payor may seek repayment of amounts previously paid for covered
products. We maintain an allowance for provider discounts and amounts intended to cover legitimate requests for repayment. Failure to
adequately identify and provide for amounts for resolution of repayment demands in our allowance for provider discounts could have a
material adverse effect on our results of operations and cash flows. For government health care programs, if we identify a deficiency in
prior claims or practices, we may be required to repay amounts previously reimbursed to us by government health care programs.
We frequently receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates
of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients,
and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if
any refund is appropriate. During the adjudication process we review claims where we are rebilling or pursuing additional reimbursement
from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are
due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund
requests, we are generally unable to determine if a refund request is valid. Although we cannot predict whether or when a request for
repayment or our subsequent request for reimbursement will be resolved, it is not unusual for such matters to be unresolved for a long
period of time. No assurances can be given with respect to our estimates for our allowance for provider discounts refund claim
reimbursements and offsets or the ultimate outcome of the refund requests.
Future changes in coverage and reimbursement policies for our products or reductions in reimbursement rates for our products by
third party payors could adversely affect our business and results of operations.
In the United States, our products are prescribed by physicians for their patients. Based on the prescription, which we consider an order,
we submit a claim for payment directly to third-party payors such as private commercial insurance carriers, government payers and
others as appropriate and the third-party payor reimburses us directly. Federal and state statutes, rules, or other regulatory measures that
restrict coverage of our products or reimbursement rates could have an adverse effect on our ability to sell or rent our products or cause
physical therapists and physicians to dispense and prescribe alternative, lower-cost products.
There are significant estimating risks associated with the amount of revenue, related refund liabilities, accounts receivable and
provider discounts that we recognize, and if we are unable to accurately estimate these amounts, it could impact the timing of our
revenue recognition, have a significant impact on our operating results or lead to a restatement of our financial results.
There are significant risks associated with the estimation of the amount of revenues, related refund liabilities, accounts receivable, and
provider discounts that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance
coverage changes, geographic coverage differences, differing interpretations of coverage, differing provider discount rates, and other
third party payor issues. Determining applicable primary and secondary coverage for our customers at any point in time, together with
the changes in patient coverage that occur each month, require complex, resource-intensive processes. Errors in determining the correct
coordination of benefits may result in refunds to payors. Revenues associated with government programs are also subject to estimating
risk related to the amounts not paid by the primary government payor that will ultimately be collectable from other government programs
paying secondary coverage, the patient’s commercial health plan secondary coverage or the patient. Collections, refunds and pay or
retractions typically continue to occur for up to three years and longer after our products are provided. While we typically look to our
past experience in collections with a payer in estimating amounts expected to be collected on current billings, recent trends and current
changes in reimbursement practice, the overall healthcare environment, and other factors nonetheless could ultimately impact the amount
of revenues recorded and the receivables ultimately collected. If our estimates of revenues, related refund liabilities, accounts receivable
or provider discounts are materially inaccurate, it could impact the timing of our revenue recognition and have a significant impact on
our operating results. It could also lead to a restatement of our financial results.
Tax laws and regulations require compliance efforts that can increase our cost of doing business and changes to these laws and
regulations could impact financial results.
We are subject to a variety of tax laws and regulations in the jurisdictions in which we do business. Maintaining compliance with these
laws can increase our cost of doing business and failure to comply could result in audits or the imposition of fines or penalties. Further,
our future effective tax rates in any of these jurisdictions could be affected, positively or negatively, by changing tax priorities, changes
in statutory rates, or changes in tax laws or the interpretation thereof. The most significant recent example of this is
10
Table of Contents
the impact of the U.S Tax Cuts and Jobs Act of 2017 (the “Tax Act”) which was enacted on December 22, 2017. These changes
significantly revised the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from 35% to
21%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings and setting limitations on
deductibility of certain costs, among other things. The Company has implemented the U.S. Tax Act and does not expect any significant
changes related to the Tax Act at this time.
The Patient Protection and Accountability act of 2010 has had an impact on our business which may be in part beneficial and in part
detrimental.
In March 2010, broad federal health care reform legislation was enacted in the United States. This legislation did not become effective
immediately in total, and may be modified prior to the effective date of some provisions. This legislation has had an impact on our
business in a variety of ways including increased number of Medicaid recipients, increased number of individuals with commercial
insurance, additional audits conducted by public health insurance plans such as Medicaid and Medicare, changes to the rules that govern
employer group health insurance and other factors that influence the acquisition and use of health insurance from private and public
payors. This legislation has resulted in a change in reimbursement for certain durable medical equipment. We believe the new healthcare
legislation and these changes to reimbursement have caused uncertainty with prescribers, which we believe contributed to our drop in
orders and revenue during 2013 and 2014 and the lack of any significant increase in 2015. Orders and revenue increased in 2016 through
2020; however, we are currently unable to determine whether such trend will continue in future periods or whether the health care reform
legislation will have other adverse consequences to our business and results of operations. To the extent prescribers write fewer
prescriptions for our products or there is an adverse change to insurance reimbursement for our products, due to the new law or
otherwise, our revenue and profitability will be materially adversely affected.
The uncertainty of continuing healthcare changes and regulations may place our business model in doubt.
There is some doubt on the continuation of the Affordable Care Act and the legislation that the current Congress will enact to replace it,
if any. Because we cannot be certain about the continuation of the Affordable Care Act or any changes or replacements thereto, even if
the Affordable Care Act remains the law of the land, there is also some doubt whether the President will support it or take regulatory
action to negatively impact its benefits. The amount of uncertainty creates concern on our customer’s willingness to buy products which
may, or may not, be covered by future health care benefits even if they are covered currently.
Hospitals and clinicians may not buy, prescribe or use our products in sufficient numbers, which could result in decreased revenues
and profits.
Hospitals and clinicians may not accept any of our products as effective, reliable, or cost-effective. Factors that could prevent such
institutional patient acceptance include:
● If patients conclude that the costs of these products exceed the cost savings associated with the use of these products;
● If patients are financially unable to purchase these products;
● If adverse patient events occur with the use of these products, generating adverse publicity;
● If we lack adequate resources to provide sufficient education and training to our patients;
● If frequent product malfunctions occur, leading clinicians to believe that the products are unreliable;
● Uncertainty regarding or change in government or third-party payor reimbursement policies for our products; and
● If physicians or other health care providers believe that our products will not be reimbursed by insurers or decide to
prescribe competing products.
11
Table of Contents
Because our sales are dependent on prescriptions from physicians, if any of these or other factors result in fewer prescriptions for our
products being written, we will have reduced revenues and may not be able to fully fund our operations. Although we experienced an
increase in orders for our ZMI products during 2019 and 2020 compared to prior years, we can make no assurances that demand for our
products will not decline in future periods.
Any new competitor could be larger than us and have greater financial and other resources than we do, and those advantages could
make it difficult for us to compete with them.
Many competitors to our products may have substantially greater financial, technical, marketing, and other resources. Competition could
result in fewer orders, reduced gross margins, and loss of market share. Our products are regulated by the FDA in the United States.
Competitors may develop products that are substantially equivalent to our FDA-cleared products, thereby using our products as predicate
devices to more quickly obtain FDA approval for their own products. If overall demand for our products should decrease it could have a
material adverse effect on our operating results. Substantial competition is expected in the future in the area of stroke rehabilitation that
may directly compete with our NeuroMove product. These competitors may use standard or novel signal processing techniques to detect
muscular movement and generate stimulation to such muscles. Other companies may develop rehabilitation products that perform better
and/or are less expensive than our products, which could have a material adverse effect on our operating results.
Failure to keep pace with the latest technological changes could result in decreased revenues.
The market for some of our products is characterized by rapid change and technological improvements. Failure to respond in a timely
and cost-effective way to these technological developments could result in serious harm to our business and operating results. We have
derived, and we expect to continue to derive, a substantial portion of our revenues from the development and sale of products in the
medical device industry. As a result, our success will depend, in part, on our ability to develop and market product offerings that respond
in a timely manner to the technological advances of our competitors, evolving industry standards and changing patient preferences. There
is no assurance that we will keep up with technological improvements.
Our business could be adversely affected by reliance on sole suppliers.
Notwithstanding our current multiple supplier approach, certain essential product components may be supplied in the future by sole, or a
limited group of, suppliers. Most of our products and components are purchased through purchase orders rather than through long term
supply agreements and large volumes of inventory may not be maintained. There may be shortages and delays in obtaining certain
product components. Disruption of the supply or inventory of components could result in a significant increase in the costs of these
components or could result in an inability to meet the demand for our products. In addition, if a change in the manufacturer of a key
component is required, qualification of a new supplier may result in delays and additional expenses in meeting customer demand for
products. These factors could adversely affect our revenues and ability to retain our experienced sales force.
A third-party manufacturer’s inability to produce our goods on time and to our specifications could result in lost revenue.
Third-party manufacturers assemble and manufacture components of the NexWave and NeuroMove and some of our other products to
our specifications. The inability of a manufacturer to ship orders of our products in a timely manner or to meet our quality standards
could cause us to miss the delivery date requirements of our patients for those items, which could result in cancellation of orders, refusal
to accept deliveries or a reduction in purchase prices, any of which could have a material adverse effect on our revenues. Because of the
timing and seriousness of our business, and the medical device industry in particular, the dates on which patients need and require
shipments of products from us are critical. Further, because quality is a leading factor when patients, doctors, health insurance providers
and distributors accept or reject goods, any decline in quality by our third-party manufacturers could be detrimental not only to a
particular order, but also to our future relationship with that particular patient.
If we need to replace manufacturers, our expenses could increase resulting in smaller profit margins.
We compete with other companies for the production capacity of our manufacturers and import quota capacity. Some of these
competitors have greater financial and other resources than we have, and thus have an advantage in the competition for production and
import quota capacity. If we experience a significant increase in demand, or if we need to replace an existing manufacturer, we may have
to expand our third-party manufacturing capacity. We cannot assure that this additional capacity will be available when required
12
Table of Contents
on terms that are acceptable to us or similar to existing terms, which we have with our manufacturers, either from a production
standpoint or a financial standpoint. We enter into a number of purchase order commitments specifying a time for delivery, method of
payment, design and quality specifications and other standard industry provisions, but do not have long-term contracts with any
manufacturer. None of the manufacturers we use produce our products exclusively. Should we be forced to replace one or more of our
manufacturers, we may experience increased costs or an adverse operational impact due to delays in distribution and delivery of our
products to our patients, which could cause us to lose patients or lose revenue because of late shipments.
We are a relatively small company with a limited number of products and staff. Sales fluctuations and employee turnover may
adversely affect our business.
We are a relatively small company. Consequently, compared to larger companies, sales fluctuations could have a greater impact on our
revenue and profitability on a quarter-to-quarter and year-to-year basis and delays in patient orders could cause our operating results to
vary significantly from quarter to quarter and year-to-year. In addition, as a small company we have limited staff and are heavily reliant
on certain key personnel to operate our business. If a key employee were to leave the company it could have a material impact on our
business and results of operations as we might not have sufficient depth in our staffing to fill the role that was previously being
performed. A delay in filling the vacated position could put a strain on existing personnel or result in a failure to satisfy our contractual
obligations or to effectively implement our internal controls, and materially harm our business.
If we are unable to retain the services of Mr. Sandgaard or if we are unable to successfully recruit qualified managerial and sales
personnel, we may not be able to continue our operations.
Our success depends to a significant extent upon the continued service of Mr. Thomas Sandgaard, our Chief Executive Officer, Founder,
and beneficial owner of approximately 44% of our outstanding stock. Loss of the services of Mr. Sandgaard could have a material
adverse effect on our growth, revenues, and prospective business. There is currently no employment agreement with Mr. Sandgaard. We
do not maintain key-man insurance on the life of Mr. Sandgaard. In addition, in order to successfully implement and manage our
business plan, we will be dependent upon, among other things, successfully retaining and recruiting qualified managerial and sales
personnel. Competition for qualified individuals is intense. Various factors, such as marketability of our products, our reputation, our
liquidity, and sales commission structure can affect our ability to find, attract or retain sales personnel. There can be no assurance that we
will be able to find and attract qualified new employees and sales representatives and retain existing employees and sales representatives.
We need to maintain insurance coverage, which could become very expensive or have limited availability.
Our marketing and sales of medical device products creates an inherent risk of claims for product liability. As a result, we carry product
liability insurance and will continue to maintain insurance in amounts we consider adequate to protect us from claims. We cannot,
however, be assured that we have resources sufficient to satisfy liability claims in excess of policy limits if required to do so. Also, if we
are subject to such liability claims, there is no assurance that our insurance provider will continue to insure us at current levels or that our
insurance rates will not substantially rise in the future, resulting in increased costs to us or forcing us to either pay higher premiums or
reduce our coverage amounts, which would result in increased liability to claims.
We depend upon obtaining regulatory approval of any new products and/or manufacturing operations we develop and maintain
approvals of current products; failure to obtain or maintain such regulatory approvals could result in increased costs, lost revenue,
penalties and fines.
Before marketing any new products, we will need to complete one or more clinical investigations of each product. There can be no
assurance that the results of such clinical investigations will be favorable to us. We may not know the results of any study, favorable or
unfavorable to us, until after the study has been completed. Such data must be submitted to the FDA as part of any regulatory filing
seeking approval to market the product. Even if the results are favorable, the FDA may dispute the claims of safety, efficacy, or clinical
utility and not allow the product to be marketed. The sales price of the product may not be enough to recoup the amount of our
investment in conducting the investigative studies and we may expend significant funds on research and development on products that
are rejected by the FDA. Some of our products are marketed based upon our interpretation of FDA regulation allowing for changes to an
existing device. If our interpretations are incorrect, we could suffer consequences that could have a material adverse effect on our results
of operations and cash flows and could result in fines and penalties. There can be no assurance that we will have the financial
13
Table of Contents
resources to complete development of any new products or to complete the regulatory approval process or to maintain regulatory
compliance of existing products.
We may not be able to obtain clearance of a 510(k) notification or approval of a de novo or pre-market approval application with
respect to any products on a timely basis, if at all.
If timely FDA clearance or approval of new products is not obtained, our business could be materially adversely affected. Clearance of a
510(k) notification or de novo application may also be required before marketing certain previously marketed products, which have been
modified after they have been cleared. Should the FDA so require, the filing of a new 510(k) notification for the modification of the
product may be required prior to marketing any modified device. To determine whether adequate compliance has been achieved, the
FDA may inspect our facilities at any time. Such compliance can be difficult and costly to achieve and maintain. Our compliance status
may change due to future changes in, or interpretations of, FDA regulations or other regulatory agencies. Such changes may result in the
FDA withdrawing marketing clearance or requiring product recall. In addition, any changes or modifications to a device or its intended
use may require us to reassess compliance with good manufacturing practices guidelines, potentially interrupting the marketing and sale
of products. We may also fail to comply with complex FDA regulations due to their complexity or otherwise. Failure to comply with
regulations could result in enforceable actions, including product seizures, product recalls, withdrawal of clearances or approvals, and
civil and criminal penalties, any of which could have a material adverse effect on our operating results and reputation.
Our products are subject to recall even after receiving FDA or foreign clearance or approval, which would harm our reputation and
business.
We are subject to medical device reporting regulations that require us to report to the FDA or respective governmental authorities in
other countries if our products cause or contribute to a death or serious injury or malfunction in a way that would be reasonably likely to
contribute to death or serious injury if the malfunction were to recur. The FDA and similar governmental authorities in other countries
have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacturing. A
government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design defects,
including defects in labeling.
Any recall would divert managerial and financial resources and could harm our reputation with customers. We cannot assure you that we
will not have product recalls in the future or that such recalls would not have a material adverse effect on our business. We have not
undertaken any voluntary or involuntary recalls to date.
We continue to incur expenses.
This area of medical device research is subject to rapid and significant technological changes. Developments and advances in the medical
industry by either competitors or other parties can affect our business in either a positive or negative manner. Developments and changes
in technology that are favorable to us may significantly advance the potential of our research while developments and advances in
research methods outside of the methods we are using may severely hinder, or halt completely our development.
We are a small company in terms of employees, technical and research resources. We expect to incur research and development, sales
and marketing, and general and administrative expenses. These amounts may increase, and recently have in connection with our efforts
to expand our sales force, before any commensurate incremental revenue from these efforts may be obtained and may adversely affect
our potential profits and we may lack the liquidity to pay for such expenditures. These factors may also hinder our ability to meet
changes in the medical industry as rapidly or effectively as competitors with more resources.
Substantial costs could be incurred defending against claims of infringement.
Other companies, including competitors, may obtain patents or other proprietary rights that would limit, interfere with, or otherwise
circumscribe our ability to make, use, or sell products. Should there be a successful claim of infringement against us and if we could not
license the alleged infringed technology at a reasonable cost, our business and operating results could be adversely affected. There has
been substantial litigation regarding patent and other intellectual property rights in the medical device industry. The validity and breadth
of claims covered in medical technology patents involve complex legal and factual questions for which important legal
14
Table of Contents
principles remain unresolved. Any litigation claims against us, independent of their validity, may result in substantial costs and the
diversion of resources with no assurance of success. Intellectual property claims could cause us to:
● Cease selling, incorporating, or using products that incorporate the challenged intellectual property;
● Obtain a license from the holder of the infringed intellectual property right, which may not be available on reasonable
terms, if at all; and
● Re-design our products excluding the infringed intellectual property, which may not be possible.
We may be unable to protect our trademarks, trade secrets and other intellectual property rights that are important to our business.
We consider our trademarks, trade secrets, and other intellectual property an integral component of our success. We rely on trademark
law and trade secret protection and confidentiality agreements with employees, customers, partners, and others to protect our intellectual
property. Effective trademark and trade secret protection may not be available in every country in which our products are available. We
obtained utility patents on the blood volume monitor in 2021 and 2018 in the U.S. and in 2020 in Europe. We cannot be certain that we
have taken adequate steps to protect our intellectual property, especially in countries where the laws may not protect our rights as fully as
in the United States. In addition, if our third-party confidentiality agreements are breached, there may not be an adequate remedy
available to us. If our trade secrets become publicly known, we may lose competitive advantages.
We may fail to protect the privacy, integrity and security of customer information.
We possess and process sensitive customer information and Protected Health Information protected by the Health Insurance Portability
and Affordability Act (“HIPAA”). While we have taken reasonable and appropriate steps to protect that information, if our security
procedures and controls were compromised, it could harm our business, reputation, results of operations and financial condition and may
increase the costs we incur to protect against such information security breaches, such as increased investment in technology, the costs of
compliance with health care privacy and consumer protection laws. A compromise of our privacy or security procedures could also
subject us to liability under certain health care privacy laws applicable to us.
Cyber-attacks and security vulnerabilities could lead to reduced revenue, increased costs, liability claims, or harm to our competitive
position.
Increased sophistication and activities of perpetrators of cyber-attacks have resulted in an increase in information security risks in recent
years. Hackers develop and deploy viruses, worms, and other malicious software programs that attack products and services and gain
access to networks and data centers. If we experience difficulties maintaining existing systems or implementing new systems, we could
incur significant losses due to disruptions in our operations. Additionally, these systems contain valuable proprietary and confidential
information and may contain personal data of our customers. A security breach could result in disruptions of our internal systems and
business applications, harm to our competitive position from the compromise of confidential business information, or subject us to
liability under laws that protect personal data. As cyber threats continue to evolve, we may be required to expend additional resources to
continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities. Any
of these consequences would adversely affect our revenue and margins.
Expansion of our operations and sales internationally may subject us to additional risks, including risks associated with unexpected
events.
A component of our growth strategy is to expand our operations and sales internationally. There can be no assurance that we will be able
to successfully market, sell, and deliver our products in foreign markets, or that we will be able to successfully expand our international
operations. Global operations could cause us to be subject to unexpected, uncontrollable and rapidly changing risks, events, and
circumstances.
The following factors, among others, could adversely affect our business, financial condition and results of operations:
● difficulties in managing foreign operations and attracting and retaining appropriate levels of senior management and
staffing;
15
Table of Contents
● longer cash collection cycles;
● proper compliance with local tax laws which can be complex and may result in unintended adverse tax consequences;
● difficulties in enforcing agreements through foreign legal systems;
● failure to properly comply with U.S. and foreign laws and regulations applicable to our foreign activities including, without
limitation, product approval, healthcare and employment law requirements and the Foreign Corrupt Practices Act;
● fluctuations in exchange rates that may affect product demand and may adversely affect the profitability in U.S. dollars of
the products we provide in foreign markets;
● the ability to efficiently repatriate cash to the United States and transfer cash between foreign jurisdictions; and
● changes in general economic conditions or political circumstances in countries where we operate.
Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect
our reported results of operations.
We are required to prepare our financial statements in accordance with generally accepted accounting principles in the United States of
America (“GAAP”), which is periodically revised and/or expanded. From time to time, we are required to adopt new or revised
accounting standards issued by recognized authoritative bodies, including the FASB and the SEC. It is possible that future accounting
standards we are required to adopt may require additional changes to the current accounting treatment that we apply to our financial
statements and may require us to make significant changes to our reporting systems. Such changes could result in a material adverse
impact on our business, results of operations and financial condition.
RISKS RELATING TO OUR COMMON STOCK
Sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price
of our common stock
Sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price of
our common stock. Mr. Sandgaard’s stock ownership may discourage a potential acquirer from making a tender offer or otherwise
attempting to obtain control of the Company, which in turn could reduce our stock price or prevent our stockholders from realizing a
premium over our stock price.
Our existing shareholders may experience dilution if we elect to raise equity capital
Due to our past liquidity issues, we have had to raise capital in the form of debt and/or equity to meet our working capital needs. As
recent as July 2020, we did raise capital through the issuance of equity to meet our working capital needs and to execute on our business
strategy. We may also choose to issue equity or debt securities in the future to meet our liquidity or other needs which would result in
additional dilution to our existing stockholders. Although we will attempt to minimize the dilutive impact of any future capital-raising
activities, we cannot offer any assurance that we will be able to do so. We may have to issue additional shares of our common stock at
prices at a discount from the then-current market price of our common stock. If we raise additional working capital, existing shareholders
may experience dilution.
We paid a dividend on our common stock, and cash used to pay dividends will not be available for other corporate purposes
In 2018, our Board of Directors declared a special one-time dividend of $0.07 per share, which was paid in January 2019. The decision to
pay dividends in the future will depend on general business conditions, the impact of such payment on our financial condition, and other
factors our Board of Directors may consider. If we elect to pay future dividends, this could reduce our cash reserves to levels that may be
inadequate to fund expansions to our business plan or unanticipated contingent liabilities.
16
Table of Contents
Our stock price could become more volatile and your investment could lose value.
All of the factors discussed in this section could affect our stock price. A significant drop in our stock price could also expose us to the
risk of securities class actions lawsuits, which could result in substantial costs and divert management’s attention and resources, which
could adversely affect our business.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
In October 2017, we signed a lease for a new corporate headquarters in Englewood, Colorado beginning in January 2018. In March 2019,
we signed an amendment to this lease, which allowed the Company to expand its corporate offices. An additional amendment was
entered into on January 3, 2020 which expanded our corporate offices to approximately 108,227 square feet. The lease and subsequent
amendments continue through June 30, 2023 with an option for a two-year extension through June 2025.
In addition to our corporate headquarters, we entered into a lease agreement for a warehouse and production facility with approximately
50,488 square feet in September 2020. The lease continues through June 2026 with an option for a five-year extension through June
2031.
We believe these leased properties are sufficient to support our current requirements and that we will be able to locate additional facilities
as needed. See Note 9 to the Consolidated Financial Statements for additional information on these leases.
ITEM 3. LEGAL PROCEEDINGS
We are not a party to any material pending legal proceedings.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES
On February 12, 2019, our common stock began trading on The Nasdaq Capital Market under the symbol “ZYXI”. Prior to uplisting to
the Nasdaq Capital Market, the Company’s common stock was quoted on the OTCQB (managed by OTC Markets, Inc) under the symbol
“ZYXI.”
As of February 25, 2021, there were 34,849,482 shares of common stock outstanding and approximately 246 record holders of our
common stock.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
17
Table of Contents
Dividends
Our Board of Directors declared a one-time special cash dividend of $0.07 per share during the fourth quarter of 2018, which was paid in
January 2019. There can be no guarantee that we will continue to pay dividends. Any future determination to pay cash dividends will be
at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements
and such other factors as the Board deems relevant.
ITEM 6. SELECTED FINANCIAL DATA
Not required
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
This Annual Report on Form 10-K contains statements that are forward-looking, such as statements relating to plans for future organic
growth and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing
sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in
the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the
Company. These risks include the ability to engage effective sales representatives, the need to obtain FDA clearance and CE marking of
new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the
reimbursement from insurance companies for products sold or leased to our customers, acceptance of our products by health insurance
providers for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our
dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation
of our sales strategy including a strong direct sales force, and other risks described herein and included in “Item 1A-Risk Factors.”
OVERVIEW
We operate in one primary business segment, electrotherapy and pain management products. As of December 31, 2020, the Company’s
only active subsidiary is ZMI, a wholly-owned Colorado corporation, through which the Company conducts its U.S. electrotherapy and
pain management operations. ZMS, a wholly-owned Colorado corporation, has developed a blood volume monitoring device, which has
received two utility patents and FDA approval in the U.S. However, ZMS has achieved no revenues to date.
The following information should be read in conjunction with our Consolidated Financial Statements and related notes contained in this
Annual Report.
HIGHLIGHTS
During the year ended December 31, 2020, the Company achieved the following:
● Expanded our sales force as we exceeded 500 sales reps at year-end. That represented a 227% increase over 2019 and
allowed us to expand into 170 territories during 2020. We expect to have approximately 600 sales reps by the end of 2021;
● Achieved a 96% increase in order growth and a 76% growth in revenue from the prior year;
● Completed an equity offering in July 2020 which netted us $25.2 million. This allowed us to further strengthen our balance
sheet without adding debt;
● Increased inventory on-hand at year-end by 263%, ensuring that we have enough product to meet future demand and serve
more patients in pain; and
18
Table of Contents
● Leased a 50,488 square foot warehouse facility, which will improve the efficiency of our production and assembly teams
and allow us to scale our distribution operations. This new facility also allows expansion at our corporate headquarters to
support the growth of our reimbursement, sales support, and other G&A functions.
SUMMARY
Net revenue increased 76% in 2020 to $80.1 million from $45.5 million in 2019. Net income was $9.1 million and $9.5 million for the
years ended December 31, 2020 and 2019, respectively. Net income decreased during 2020 as a result of an increased investment in our
sales force and accompanying infrastructure.
We generated cash flows from operating activities of $0.8 million during the year ended December 31, 2020. Increased orders for our
devices and supplies and the related receivables and cash flows, along with an equity raise completed in July 2020, allowed us to grow
our working capital at December 31, 2020 to $52.9 million, compared to $17.4 million as of December 31, 2019.
RESULTS OF OPERATIONS
The following table presents our consolidated statements of operations in comparative format (in thousands).
NET REVENUE
Devices
Supplies
Total net revenue
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue – devices and supplies
Sales and marketing
General and administrative
Total costs of revenue and operating expenses
Income from operations
Other income/(expense)
Deferred insurance reimbursement
Loss on disposal of non-controlling interest
Interest expense
Other income/(expense), net
Income from operations before income taxes
Income tax expense
Net Income
Net income per share:
Basic
Diluted
19
For the Years Ended
December 31,
2020
2019
$
change
$
$
21,269
58,853
80,122
$
10,713
34,759
45,472
17,417
34,133
18,323
69,873
10,249
—
(77)
(19)
(96)
10,153
1,079
9,074
0.27
0.26
$
$
$
8,814
14,855
10,737
34,406
11,066
880
—
(5)
875
11,941
2,449
9,492
0.29
0.28
$
$
$
$
$
$
10,556
24,094
34,650
8,603
19,278
7,586
35,467
(817)
(880)
(77)
(14)
(971)
(1,788)
(1,370)
(418)
(0.02)
(0.02)
Table of Contents
The following table presents our consolidated statements of operations reflected as a percentage of total revenue:
NET REVENUE
Devices
Supplies
Total net revenue
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue – devices and supplies
Sales and marketing
General and administrative
Total costs of revenue and operating expenses
Income from operations
Other income/(expense)
Deferred insurance reimbursement
Interest expense
Other income/(expense), net
Income from operations before income taxes
Income tax expense
Net Income
Net Revenue
For the Years Ended December 31,
2020
2019
27 %
73 %
100 %
22 %
43 %
23 %
87 %
13 %
0 %
0 %
0 %
13 %
1 %
12 %
24 %
76 %
100 %
19 %
33 %
24 %
76 %
24 %
2 %
0 %
2 %
26 %
5 %
21 %
Net revenues are comprised of device and supply sales, constrained by estimated third-party payor reimbursement deductions. The
reserve for billing allowance adjustments and allowance for uncollectible accounts are adjusted on an ongoing basis in conjunction with
the processing of third-party payor insurance claims and other customer collection history. Product device revenue is primarily comprised
of sales and rentals of our electrotherapy products and also includes complimentary products such as our cervical traction, lumbar
support and hot/cold therapy products.
Supplies revenue is primarily comprised of sales of our consumable supplies to patients using our electrotherapy products, consisting
primarily of surface electrodes and batteries. Revenue related to both devices and supplies is reported net, after adjustments for estimated
third-party payor reimbursement deductions and estimated allowance for uncollectible accounts. The deductions are known throughout
the health care industry as billing adjustments whereby the healthcare insurers unilaterally reduce the amount they reimburse for our
products as compared to the sales prices charged by us. The deductions from gross revenue also take into account the estimated denials,
net of resubmitted billings of claims for products placed with patients which may affect collectability. See our Significant Accounting
Policies in Note 2 to the Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.
We occasionally receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and
dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few
patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and
determine if any refund is appropriate. We also review claims that have been resubmitted or where we are pursuing additional
reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in
amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of
such refund requests we are generally unable to determine if a refund request is valid.
Net revenue increased $34.6 million or 76% to $80.1 million for the year ended December 31, 2020, from $45.5 million for the year
ended December 31, 2019. The growth in net revenue is primarily related to the 96% growth in device orders which led to an
20
Table of Contents
increased customer base and drove higher sales of consumable supplies. During 2020, the Company increased its direct sales force by
approximately 227% from 2019 and entered 170 new territories, which led to the significant increase in orders during 2020.
Device Revenue
Device revenue is related to the purchase or lease of our electrotherapy products as well as complimentary products including cervical
traction, lumbar support and hot/cold therapy products. Device revenue increased $10.6 million or 99% to $21.3 million for the year
ended December 31, 2020, from $10.7 million for the year ended December 31, 2019. The increase in device revenue is related to the
growth in our device and complimentary product orders of 96% from 2019 to 2020 as a result of our increased sales force and additional
territories as discussed above.
Supplies Revenue
Supplies revenue is related to the sale of supplies, typically electrodes and batteries, for our products. Supplies revenue increased $24.1
million or 69% to $58.9 million for the year ended December 31, 2020, from $34.8 million for the year ended December 31, 2019. The
increase in supplies revenue is primarily related to growth in our customer base from higher device sales in 2020.
Operating Expenses
Costs of Revenue –Devices and Supplies
Costs of revenue – devices and supplies consist primarily of device and supplies costs, operations labor and overhead, shipping and
depreciation. Costs of revenue increased $8.6 million or 97% to $17.4 million for the year ended December 31, 2020, from $8.8 million
for the year ended December 31, 2019. The increase in costs of revenue is directly related to the increase in device and supplies orders.
As a percentage of revenue, cost of revenue –devices and supplies increased to 22% for the year ended December 31, 2020 compared to
19% for the year ended December 31, 2019. The increase in cost of revenue – devices and supplies as a percentage of revenue was due
to increased tariff and shipping costs during the year as well as an increase in labor as the company added an additional management
layer within production to support its growing production workforce.
Sales and Marketing Expense
Sales and marketing expense primarily consists of employee-related costs, including commissions and other direct costs associated with
these personnel including travel and marketing expenses. Sales and marketing expense for the year ended December 31, 2020 increased
130% to $34.1 million from $14.9 million for the year ended December 31, 2019. The increase in sales and marketing expense is
primarily due to an increase of approximately 227% in our direct sales force by adding 304 additional salaried sales reps over the past 12
months. As a percentage of revenue, sales and marketing expense increased to 43% for the year ended December 31, 2020 from 33% for
the year ended December 31, 2019. The increase as a percentage of revenue is primarily due to our overall effort to expand our sales
force and the related ramp-up period as territory managers build their sales territory.
General and Administrative Expense
General and administrative expense primarily consists of employee related costs, facilities expense, professional fees and depreciation
and amortization. General and administrative expense for the year ended December 31, 2020 increased 71% to $18.3 million from $10.7
million for the year ended December 31, 2019. The increase in general and administrative expense is primarily due to the following:
● an increase of $5.5 million in compensation and benefits expense, including non-cash stock compensation expense, related
to headcount growth. During 2020, the Company increased its headcount for its general and administrative activities by
approximately 132%, or 162 employees;
● an increase of $1.6 million in other expenses, including professional fees and temporary labor costs; and
● an increase of $0.6 million in rent and facilities expenses as we further expanded our corporate offices in April 2020 to
include all four floors at our current corporate headquarters.
21
Table of Contents
As a percentage of revenue, general and administrative expense decreased to 23% for the year ended December 31, 2020 from 24% for
the year ended December 31, 2019. The decrease as a percentage of revenue is primarily due to leveraging our investment in general and
administrative functions from prior years.
The Company expects that general and administrative expenses will continue to increase through 2021 as the Company continues to
expand its corporate headcount to accommodate continued order growth.
Other Income (Expense)
Other expense was $96,000 for the year ended December 31, 2020, of which $19,000 was related to interest on our finance lease
obligations and $77,000 was related to the dissolution of our ZBC subsidiary. The loss upon dissolution was the result of the non-
controlling interest of $89,000, which was offset by a write-off of liabilities of $12,000. The Company dissolved ZBC due to inactivity,
and the Company has no plans to re-start ZBC business activities.
Other income was $0.9 million for the year ended December 31, 2019 which was related to a deferred insurance reimbursement from the
first quarter of 2016. The Company collected $0.9 million from an insurance company for accounts receivable. Subsequent to March 31,
2016, the insurance company verbally communicated to the Company that this payment was made in error and requested it be refunded
to the insurance company. The Company recorded this $0.9 million as a deferred insurance liability.
During the first quarter of 2019, the Company recognized $0.9 million as other income and released the liability. The Company has
included this amount in other income in order to ensure comparability of the Company’s operating income results for the years ended
December 31, 2019 and 2018. Management’s legal determination that any refund obligation is remote was based on the facts and
circumstances related to the dispute, which included reviewing the legal statutes within the jurisdictions the Company operates.
Income Tax Expense
We recorded income tax expense of $1.1 million and $2.4 million for the years ended December 31, 2020 and 2019, respectively. The
effective income tax rate for the years ended December 31, 2020 and 2019 was 10% and 20%, respectively. The decrease in expense and
effective rate during 2020 is primarily due to an increase in deductions related to stock-based compensation vesting and exercises.
During 2020, discrete items related to stock-based compensation was $1.7 million as compared with $0.8 million in 2019.
FINANCIAL CONDITION
As of December 31, 2020, we had working capital of $52.9 million, compared to $17.4 million as of December 31, 2019. The increase in
working capital is primarily due to the Company’s increase in orders and related receivables during 2020 along with the completion of a
public offering whereby the Company received net proceeds of $25.2 million in July 2020. We generated $0.8 million in operating cash
flows during 2020.
LIQUIDITY AND CAPITAL RESOURCES
We have historically financed operations through cash flows from operations, debt and equity transactions. As of December 31, 2020,
our principal source of liquidity was $39.2 million in cash and $13.8 million in accounts receivables. The increased cash balance at
December 31, 2020 was primarily due to the completion of a public offering in July 2020 which netted the Company proceeds of $25.2
million.
Our anticipated uses of cash in the future will be to fund the expansion of our business. The Company does not anticipate any large
expenditures for capital resources over the next 12 months.
Net cash provided by operating activities for the years ended December 31, 2020 and 2019 was $0.8 million and $6.3 million,
respectively. The decrease in cash provided by operating activities for the year ended December 31, 2020 was primarily due to an
increase in the amount of inventory the Company purchased during 2020 in order to keep up with increased demand and increased
accounts receivable due to revenue growth.
22
Table of Contents
Net cash used in investing activities for the years ended December 31, 2020 and 2019 was $1.0 million and $0.2 million,
respectively. Cash used in investing activities for the years ended December 31, 2020 was primarily related to the purchase of computer
and office equipment. Cash used in investing activities for the year ended December 31, 2019 was primarily related to the purchase of
computer and office equipment.
Net cash provided by financing activities for the year ended December 31, 2020 was $25.3 million compared with net cash used in
financing activities of $2.2 million for the 2019 period. The cash provided by financing activities for the year ended December 31, 2020
was primarily due to the completion of a public equity offering in July 2020 for net proceeds of $25.2 million along with net proceeds
from the exercise of stock options of $0.1 million. The cash used in financing activities for the year ended December 31, 2019 was
primarily due to the payment of a $2.3 million dividend in January 2019.
We believe our cash and cash equivalents, together with anticipated cash flow from operations will be sufficient to meet our working
capital, and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the
following:
● Our cash and cash equivalents balance at December 31, 2020 of $39.2 million;
● Our working capital balance of $52.9 million;
● Our accounts receivable balance of $13.8 million:
● Our profitability during the last 18 quarters; and
● Our planned capital expenditures of less than $1.0 million during 2021.
Contractual Obligations
The following table summarizes the future cash disbursements to which we are contractually committed as of December 31, 2020 (in
thousands).
Operating leases
Finance leases
Total
7,576
427
2021
2,352
105
2022
2,447
105
2023
1,514
105
$
8,003
$
2,457
$
2,552
$
1,619
$
512
77
589
$
2024
2025
Thereafter
223
—
223
$
528
35
563
We lease office and warehouse facilities under non-cancelable operating leases. The current office facility leases include our corporate
headquarters and a production warehouse, both located in Englewood, Colorado. We also rent a small warehouse/office in Denmark.
Rent expense was $1.7 million and $1.0 million for the years ended December 31, 2020 and 2019, respectively.
The Company also leases office equipment for its corporate and warehouse facilities under non-cancelable finance lease agreements.
Off – Balance Sheet Arrangements
As of December 31, 2020, and 2019, we had no off-balance sheet arrangements or obligations.
SUBSEQUENT EVENT
Appointment of Chief Operating Officer
On January 28, 2021, the Company announced the promotion of Anna Lucsok to Chief Operating Officer. Additionally, on such date, the
Company entered into an employment agreement with Ms. Lucsok which was included as an exhibit to the Current Report on Form 8-K
filed on the same date.
23
Table of Contents
CRITICAL ACCOUNTING POLICIES
Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been
prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
We have identified the policies below as critical to our business operations and the understanding of our results of operations.
Revenue Recognition and Accounts Receivable
Revenue is generated primarily from sales and leases of our electrotherapy devices and related supplies and complimentary products.
Sales are primarily made with, and shipped, direct to the patient with a small amount of revenue generated from sales to distributors.
In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and
supplies. The terms of the separate arrangement impact certain aspects of the contract with patients covered by third party payers, such as
contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer
refers to the arrangement between the Company and the patient.
The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon
delivery of goods to the patient.
Device Sales
Device sales can be in the form of a purchase or a lease.
Revenue for purchased devices is recognized in accordance with ASC 606 – “Revenue from Contracts with Customers” (“ASC 606)
when the device is delivered to the patient.
Revenue related to devices out on lease is recognized in accordance with ASC 842, Leases. Using the guidance in ASC 842, we
concluded our transactions should be accounted for as operating leases based on the following criteria below:
● The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.
● The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to
exercise.
● The lease term is month to month, which does not meet the major part of the remaining economic life of the underlying
asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion
shall not be used for purposes of classifying the lease.
● There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed
substantially all of the fair value of the underlying asset
● The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.
Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices
are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at
any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.
Supplies
Supplies revenue is recognized once delivered to the patient. Supplies needed for the device can be set up as a recurring shipment or
ordered through the customer support team or online store as needed.
24
Table of Contents
Variable consideration
A significant portion of the Company’s revenues are derived, and the related receivables are due, from patients with commercial or
government health plans. Revenues are estimated using the portfolio approach by third party payer type based upon historical rates of
collection, the aging of receivables, trends in the historical reimbursement rates by third-party payer types and current relationships and
experience with the third-party payers, which includes estimated constraints for third-party payer refund requests, deductions and
adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and
constraints are released. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts
for certain products from third-party payers or unanticipated requirements to refund payments previously received may result in
adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payer reimbursement,
it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and
cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue
in the period when such final determinations are known. Historically these differences have been immaterial and the Company has not
had to go back and reassess the adjustments of future periods for past billing adjustments.
The Company monitors the variability and uncertain timing over third-party payer types in our portfolios. If there is a change in our
third-party payer mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of
collection experience to estimate the net collectible amounts by third-party payer type. However, changes to constraints related to billing
adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.
Stock-based Compensation
The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an
award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during
the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide
service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For
awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable
that the performance conditions will be achieved.
Income Taxes
Significant judgment is required in determining our provision for income taxes. We assess the likelihood that our deferred tax asset will
be recovered from future taxable income, and to the extent we believe that recovery is not likely, we establish a valuation allowance. We
consider future taxable income projections, historical results and ongoing tax planning strategies in assessing the recoverability of
deferred tax assets. However, adjustments could be required in the future if we determine that the amount to be realized is less or greater
than the amount that we recorded. Such adjustments, if any, could have a material impact on our results of our operations.
We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions
taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be
sustained upon examination by taxing authorities.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risks, including changes to interest rates and inflation.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements, the notes thereto, and the report thereon of Plante & Moran PLLC, are filed as part of this report
starting on page F-1.
ITEM 9. CHANGES IN ACCOUNTANTS
None.
25
Table of Contents
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures. We maintain “disclosure controls and procedures,” as such term is defined in
Rule 13a-15(e) and 15d-15(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to provide reasonable
assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such
information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation of the Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of
our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on that
evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were
effective as of the end of such period.
In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no
matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure
controls and procedures are met. Additionally, in designing disclosure controls and procedures, we are required to apply judgment in
evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and
procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions.
Management’s report on internal control over financial reporting. Our management is responsible for establishing and maintaining
adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). All internal control systems,
no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only
reasonable assurance with respect to financial statement preparation and presentation. Under the supervision and with the participation of
our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of
our internal control over financial reporting based on the 2013 framework set forth in the report entitled Internal Control — Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). The COSO framework
summarizes each of the components of a company’s internal control system, including (i) the control environment, (ii) risk assessment,
(iii) control activities, (iv) information and communication, and (v) monitoring.
Based on our evaluation under the 2013 framework in Internal Control — Integrated Framework, our management concluded that our
internal control over financial reporting was effective as of December 31, 2020.
Changes in Internal Control over Financial Reporting
During the quarter ended December 31, 2020, there was no change in our internal control over financial reporting or in other factors that
has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
ITEM 9B. OTHER INFORMATION
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange
Commission not later than 120 days after the end of our fiscal year ended December 31, 2020 in connection with the solicitation of
proxies for the Company’s 2021 annual meeting of shareholders, and is incorporated herein by reference.
26
Table of Contents
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange
Commission not later than 120 days after the end of our fiscal year ended December 31, 2020 and is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS.
EQUITY COMPENSATION PLAN INFORMATION
The following table provides information as of December 31, 2020 regarding shares of common stock available for issuance under our
equity incentive plans (in thousands except exercise price)
Plan Category
2005 Stock Option Plan (1)
Equity Compensation Plans not approved
by Shareholders (2)
Warrants
2017 Stock Option Plan (3)
Total
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options,
Warrants
and Rights
Weighted
Average Exercise
Price of
Outstanding
Options, Warrants
and Rights
Number of Securities
Remaining Available
for Future Issuance
Under Equity
Compensation Plans
(excluding securities
reflected in the first
column)
298
$
0.30
38
100
938
1,374
$
0.28
2.63
3.16
2.42
—
—
3,568
3,568
(1) All of these securities are available for issuance under the Zynex, Inc. 2005 Stock Option Plan, approved by the Board of Directors
on January 3, 2005 and by our stockholders on December 30, 2005.
(2) As of December 31, 2014, the 2005 Stock Option Plan was terminated. Termination of the plan did not affect the rights and
obligations of the participants and the company arising under options previously granted.
(3) The 2017 Stock Option Plan was approved by shareholders on June 1, 2017.
The additional information required by this item will be included in the Proxy Statement, which will be filed with the Securities and
Exchange Commission not later than 120 days after the end of our fiscal year ended December 31, 2020 and is incorporated herein by
reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange
Commission not later than 120 days after the end of our fiscal year ended December 31, 2020 and is incorporated herein by reference.
The Board of Directors has determined that Messrs. Cress, Disbrow and Michaels who together comprise the Audit Committee, are all
“independent directors” within the meaning of Rule 5605 of the NASDAQ Listing Rules.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange
Commission not later than 120 days after the end of our fiscal year ended December 31, 2020 and is incorporated herein by reference.
27
Table of Contents
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Consolidated Financial Statements:
PART IV
Report of Independent Registered Public Accounting Firm (Plante & Moran, PLLC)
Consolidated Balance Sheets as of December 31, 2020 and 2019
Consolidated Statements of Comprehensive Income for the years ended December 31, 2020 and 2019
Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019
Notes to Consolidated Financial Statements
F-1
F-3
F-4
F-5
F-6
F-7
Exhibits:
Exhibit
Number
2.1
3.1
3.2
4.1
Description
Asset Purchase Agreement, dated March 9, 2012, among Zynex NeuroDiagnostics, Inc., NeuroDyne Medical Corp. and
the shareholders listed on Schedule A thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current
Report on Form 8-K filed on March 13, 2012)
Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 10.1 of the Company’s Current
Report on Form 8-K filed on October 7, 2008)
Amended and Restated Bylaws (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-
K filed on October 7, 2008)
Zynex, Inc 2017 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Report on form S-8
filed on September 6, 2017)
4.2
Description of registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934
10.1†
Offer Letter, dated August 16, 2010, between Zynex, Inc. and Anthony Scalese (incorporated by reference to Exhibit
10.2 of the Company's Current Report on Form 8-K filed on August 24, 2010)
10.2†
10.3†
10.4
10.5
Amended and Restated Employment Agreement, dated August 11, 2011, between Zynex, Inc. and Thomas Sandgaard
(incorporated by reference to Exhibit 10.1of the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2011.)
2005 Stock Option Plan (incorporated by reference to Exhibit 10.5 of the Company’s Annual Report on Form 10-KSB
for the year ended December 31, 2004)
Form of Indemnification Agreement for directors and executive officers (incorporated by reference to Exhibit 10.3 of the
Company’s Current Report on Form 8-K filed on October 7, 2008)
Loan and Security Agreement, dated December 19, 2011, among Zynex, Inc. Zynex Medical, Inc., Zynex
NeuroDiagnostics, Inc., Zynex Monitoring Solutions Inc. and Doral Healthcare Finance (incorporated by reference to
Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on December 20, 2011)
Amendment No.1 to Loan and Security Agreement, dated May 31, 2013, among Zynex, Inc. Zynex Medical, Inc. Zynex
NeuroDiagnostics, Inc., Zynex Monitoring Solutions, Inc. Zynex Billing and Consulting, LLC and Doral Healthcare
Finance (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2013).
28
Table of Contents
Exhibit
Number
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
10.15
10.16
10.17
Park Meadows Corporate Center III and IV Office Lease Between Public Credit Service Credit Union (Landlord) and
Zynex Medical, Inc. (Tenant). (incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2014).
Description
Forbearance Agreement, effective December 17, 2014, between Zynex, Inc. and Triumph Community Bank, N.A., dba
Triumph Healthcare Finance (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K
filed on December 24, 2014)
Amendment No. 1 To Forbearance Agreement dated March 27, 2015. (incorporated by reference to Exhibit 10.12 to the
Company’s Report on Form 10-K filed on March 31, 2015)
Amendment No. 2 To Forbearance Agreement dated June 30, 2015. (incorporated by reference to Exhibit 10.2 to the
Company’s Report on Form 10-Q filed on August 14, 2015)
Amendment No. 3 To Forbearance Agreement dated September 30, 2015. (incorporated by reference to Exhibit 10.3 to
the Company’s Report on Form 10-Q filed on November 17, 2015)
Amendment No. 4 To Forbearance Agreement dated December 15, 2015. (incorporated by reference to Exhibit 10.4 to
the Company’s Report on Form 8-K filed on December 31, 2015)
Amendment No.5 To Forbearance Agreement dated March 28, 2016 (incorporated by reference to Exhibit 10.16 to the
Company’s Report on Form 10K filed on March 31, 2016)
Amendment No. 6 to Forbearance Agreement dated June 30, 2016 (incorporated by reference to Exhibit 10.17 to the
Company’s Report on Form 10-Q filed on November 14, 2016)
Amendment No. 7 to Forbearance Agreement dated September 29, 2016 (incorporated by reference to Exhibit 10.18 to
the Company’s Report on Form 10-Q filed on November 14, 2016)
Amendment to Lease Agreement dated August 12, 2016 (incorporated by reference to Exhibit 10.19 to the Company’s
Report on Form 10-Q filed on November 14, 2016)
Amendment No.8 To Forbearance Agreement dated December 16, 2016 (incorporated by reference to Exhibit 10.1 to the
Company’s Report on Form 8-K dated December 16, 2016)
Amendment No.9 To Forbearance Agreement dated April 18, 2017 ( incorporated by reference to Exhibit 10.21 to the
Company’s Annual Report on Form 10-K dated April 17,2017)
10.18†
Employment agreement for Daniel J. Moorhead dated June 5, 2017 ( incorporated by reference of Exhibit 10.1 to the
Company’s Report on Form 8K filed on June 8, 2017)
10.20
10.21
10.22
Office Lease, effective October 20, 2017, between CSG Systems, Inc. and Zynex Medical, Inc. (incorporated by
reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on October 26, 2017).
Zynex, Inc. Non-Employee Director Compensation Plan (incorporated by reference to Exhibit 10.1 to the Company’s
Report on Form 8-K filed on January 11, 2018)
Effective October 1, 2018, EKS&H, LLLP, the Company’s independent registered accounting firm combined with
Plante & Moran, PLLC (incorporated by reference to Exhibit 16.1 to the Company’s Report on Form 8-K filed on
October 4, 2018)
29
Table of Contents
Exhibit
Number
10.23
10.24
10.25
10.26
Equity Distribution Agreement, dated October 29, 2019 between Zynex, Inc. and Piper Jaffray & Co. (incorporated by
reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K filed on October 29, 2019)
Description
Amendment to Sublease Agreement, effective January 3, 2020, between CSG Systems, Inc. and Zynex, Inc.
(incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on January 7, 2020
Underwriting Agreement dated July 14, 2020, among certain selling stockholders, Piper Sandler & Co., and Zynex, Inc.
(incorporated by reference to Exhibit 1.1 of the Company’s Report on Form 8-K filed on July 17, 2020)
Lease Agreement, effective September 30, 2020, between GIG CW Compark, LLC and Zynex, Inc. (incorporated by
reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on October 6, 2020).
21*
Subsidiaries of the Company
23.1*
Consent of Plante & Moran, PLLC, Independent Registered Public Accounting Firm (Filed herewith)
31.1*
31.2*
32.1*
32.2*
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of
Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of
Sarbanes-Oxley Act of 2002
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Calculation Linkbase Document
101.LAB*
XBRL Taxonomy Label Linkbase Document
101.PRE*
XBRL Presentation Linkbase Document
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
Filed herewith
*
† Denotes management contract or compensatory plan or arrangement
30
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 25, 2021
ZYNEX, INC.
By : /s/ Thomas Sandgaard
Thomas Sandgaard
Chairman, President Chief Executive Officer and Principal
Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on
behalf of the registrant and in the capacities and on the dates indicated.
Date
Name and Title
Signature
February 25, 2021
Thomas Sandgaard,
Chairman, President, Chief Executive Officer and Principal Executive Officer
/s/ Thomas Sandgaard
February 25, 2021
Daniel Moorhead
Chief Financial Officer and Principal Financial Officer
February 25, 2021
February 25, 2021
February 25, 2021
Barry D. Michaels
Director
Michael Cress
Director
Joshua R. Disbrow
Director
31
/s/ Daniel Moorhead
/s/ Barry D. Michaels
/s/ Michael Cress
/s/ Joshua R. Disbrow
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors of
Zynex, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Zynex, Inc. (the “Company”) as of December 31, 2020 and 2019, the related
consolidated statements of income, comprehensive income, stockholders' equity, and cash flows for each of the years in the two-year
period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the
financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31,
2020 and 2019, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2020,
in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
The Company's management is responsible for these financial statements. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our
audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were
communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to
the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical
audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the
critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.
Estimation of Transaction Price and Variable Consideration for Revenue Recognition including related Valuation of Accounts
Receivable – Refer to Note 2 to the Financial Statements
Critical Audit Matter Description
As described in Note 2 to the financial statements, revenue is derived from sales and leases of electrotherapy devices and sales of related
supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient,
in the amount that reflects the consideration to which the Company expects to receive. The Company estimates revenues using the
portfolio approach based upon historical rates of collection, aging of receivables, product mix, trends in historical reimbursement rates by
third-party payer types, and current relationships and experience with the third-party payers, which includes estimated variable
consideration and relevant constraints for third-party payer refund requests, deductions and adjustments.
F-1
Table of Contents
We identified the Company's estimation of transaction price related to variable consideration for revenue recognition including the
related valuation of accounts receivable as a critical audit matter. Auditing the Company's determination of variable consideration and the
related constraint for revenue recognition including the recorded value for accounts receivable was challenging and complex due to the
high degree of subjectivity involved in evaluating management’s estimates. This required a high degree of auditor judgment and
increased extent of effort to audit and evaluate management’s key judgments.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to revenue recognition and accounts receivable include the following, among others:
● We gained an understanding of the design of the controls over the Company's contracts with customers including those controls
over the processes to develop key management estimates.
● We performed testing throughout the year on a sample of contracts to test the validity of sales transactions, cash receipts
application and collection rates,
● We also performed testing throughout the year on a quarterly basis over subsequent collections on recorded receivables.
● We evaluated the significant assumptions and the accuracy and completeness of the underlying data used in management’s
calculations, including evaluating management’s estimate of historical reimbursement experience as well as expected future
payment behavior through a combination of underlying data validation by inspection of source documents, independent
recalculation of management’s analysis, inquiries with management and evaluation of trends in collection rates
● We performed independent sensitivity analyses over the Company's significant assumptions embodied within their key
estimates including evaluation of subsequent payment activity compared with management’s estimate of expected collection
rates.
/s/ Plante & Moran PLLC
We have served as the Company’s auditor since 2016.
Denver, Colorado
February 25, 2021
F-2
ZYNEX, INC.
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)
ASSETS
December 31,
2020
December 31,
2019
Table of Contents
Current assets:
Cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other
Total current assets
Property and equipment, net
Operating lease asset
Finance lease asset
Deposits
Deferred income taxes
Total assets
Current liabilities:
Accounts payable and accrued expenses
Operating lease liability
Finance lease liability
Income taxes payable
Accrued payroll and related taxes
Total current liabilities
Long-term liabilities:
Operating lease liability
Finance lease liability
Total liabilities
LIABILITIES AND STOCKHOLDERS' EQUITY
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and
December 31, 2019
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020 and
33,862,885 issued and 32,791,665 outstanding as of December 31, 2019
Additional paid-in capital
Treasury stock 1,071,220 shares, at December 31, 2020 and 2019, at cost
Retained earnings
Total Zynex, Inc. stockholders' equity
Non-controlling interest
Total stockholders' equity
Total liabilities and stockholders' equity
See accompanying notes to consolidated financial statements.
F-3
$
$
$
39,173
13,837
8,635
1,378
63,023
1,925
5,993
321
347
566
72,175
4,717
2,051
77
280
2,992
10,117
4,920
283
15,320
—
36
37,235
(3,846)
23,430
56,855
—
56,855
72,175
$
$
$
14,040
5,833
2,378
315
22,566
858
3,831
180
329
513
28,277
2,141
1,211
45
52
1,748
5,197
3,282
145
8,624
—
34
9,198
(3,846)
14,356
19,742
(89)
19,653
28,277
Table of Contents
NET REVENUE
Devices
Supplies
Total net revenue
ZYNEX, INC.
CONSOLIDATED STATEMENTS OF INCOME
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)
YEARS ENDED DECEMBER 31, 2020 AND 2019
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies
Sales and marketing
General and administrative
Total costs of revenue and operating expenses
Income from operations
Other income/(expense)
Deferred insurance reimbursement
Loss on disposal of non-controlling interest
Interest expense
Other income/(expense), net
Income from operations before income taxes
Income tax expense
Net Income
Net income per share:
Basic
Diluted
Weighted average basic shares outstanding
Weighted average diluted shares outstanding
See accompanying notes to consolidated financial statements.
F-4
For the Years Ended December 31,
2020
2019
$
$
21,269
58,853
80,122
17,417
34,133
18,323
69,873
10,249
—
(77)
(19)
(96)
10,153
1,079
9,074
0.27
0.26
33,869
34,943
$
$
$
$
$
$
10,713
34,759
45,472
8,814
14,855
10,737
34,406
11,066
880
—
(5)
875
11,941
2,449
9,492
0.29
0.28
32,439
33,963
Table of Contents
ZYNEX, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN THOUSANDS)
YEARS ENDED DECEMBER 31, 2020 AND 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
Non-cash reserve charges
Stock-based compensation
Non-cash lease expense
Provision for deferred income taxes
Change in operating assets and liabilities:
Accounts receivable
Prepaid and other assets
Accounts payable and other accrued expenses
Inventory
Deposits
Other
Net cash provided by operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations
Common stock cash dividends
Purchase of treasury stock
Proceeds from issuance of common stock under equity offering, net
Proceeds from the issuance of common stock on stock-based awards
Taxes withheld and paid on employees' equity awards
Net cash (used in) provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for rent
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities
Right-of-use assets obtained in exchange for new finance lease liabilities
Inventory transferred to sales rep demos
Inventory transferred to property and equipment under lease
See accompanying notes to consolidated financial statements.
F-5
For the Years Ended December 31,
2020
2019
$
9,074
$
9,492
1,572
(238)
2,681
2
(54)
(8,004)
(724)
3,773
(7,323)
(18)
77
818
(985)
(985)
(57)
—
—
25,203
566
(412)
25,300
25,133
14,040
39,173
(19)
(1,633)
(894)
3,834
225
519
811
$
$
$
$
$
$
$
$
778
185
820
—
212
(3,042)
255
785
(2,360)
(15)
(807)
6,303
(160)
(160)
(19)
(2,262)
(171)
—
221
—
(2,231)
3,912
10,128
14,040
(5)
(956)
(2,873)
1,605
186
—
652
$
$
$
$
$
$
$
$
Table of Contents
ZYNEX, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
YEARS ENDED DECEMBER 31, 2020 AND 2019
(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)
Balance, December 31, 2018
32,271,367
$
34
$
8,157
$
Common Stock
Shares
Amount
Additional
Paid-in
Capital
Treasury
Stock
(3,675) $
Retained
Earnings
4,864
Non-Controlling Stockholders'
Interest
Equity
$
(89) $
9,291
Total
Exercised and vested stock-based awards
Warrant exercises
Stock-based compensation expense
Treasury stock
Other
Net income
531,940
40,366
—
(52,000)
(8)
—
—
—
—
—
—
—
221
—
820
—
—
—
—
—
—
(171)
—
—
—
—
—
—
—
9,492
—
—
—
—
—
—
221
820
(171)
—
9,492
Balance at December 31, 2019
32,791,665
$
34
$
9,198
$
(3,846) $
14,356
$
(89) $
19,653
Stock issued for public offering, net of
issuance costs
Exercised and vested stock-based awards
Stock-based compensation expense
Shares of common stock withheld to pay
taxes on employees' equity awards
1,250,000
776,733
—
(26,467)
Deconsolidation of non-controlling interest
Net income
—
1
1
—
—
—
25,202
566
2,681
(412)
—
—
—
—
—
—
—
—
—
—
9,074
—
—
—
—
89
—
25,203
567
2,681
(412)
89
9,074
Balance at December 31, 2020
34,791,931
$
36
$
37,235
$
(3,846) $
23,430
$
— $
56,855
See accompanying notes to consolidated financial statements.
F-6
Table of Contents
ZYNEX, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(1) ORGANIZATION, NATURE OF BUSINESS AND MANAGEMENT’S PLANS
Organization
Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate in one primary business segment, medical
devices which include electrotherapy and pain management products. As of December 31, 2020, the Company’s only active subsidiary is
Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. Zynex
Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device which
received approval by the U.S. Food and Drug Administration (“FDA”) during 2020 and is still awaiting CE Marking in Europe;
therefore, ZMS has achieved no revenues to date. Its inactive subsidiaries include Zynex Europe, Zynex NeuroDiagnostics, Inc.
(“ZND,” a wholly-owned Colorado corporation) and Pharmazy, Inc. (“Pharmazy”), which was incorporated in June 2015 as a wholly-
owned Colorado corporation. The Company’s compound pharmacy operated as a division of ZMI dba as Pharmazy through
January 2016.
The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.
Nature of Business
The Company designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise
muscles for rehabilitative purposes with electrical stimulation. The Company’s devices are intended for pain management to reduce
reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle
stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and
transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are designed to be patient friendly and designed for home
use. Our devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via
electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a
physician’s prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed
to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and
batteries, which are shipped to patients on a recurring monthly basis, as needed.
During the years ended December 31, 2020 and 2019, the Company generated all of its revenue in North America from sales and
supplies of its devices to patients and health care providers.
(2) SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances
and transactions have been eliminated in consolidation.
Non-controlling Interest
Non-controlling interest in the equity of a subsidiary is accounted for and reported as a decrease in shareholders’ equity. Prior years’ non-
controlling interest represents the 20% ownership in the Company’s majority-owned inactive subsidiary, Zynex Billing, Corp (ZBC).
During 2020, the Company dissolved ZBC due to inactivity and no plans to restart operations. As a result, the Company recorded a loss
of $77,000 on the dissolution related to the 20% non-controlling interest, less liabilities that were written off.
F-7
Table of Contents
Reclassifications
During 2020, the Company re-allocated certain costs related to selling and marketing activities from general and administrative costs. As
a result, reclassifications between selling and marketing costs and general and administrative costs have been made to the results of
operations for the year ended December 31, 2019 to conform to the consolidated 2020 financial statement presentation. These
reclassifications resulted in an increase of $0.8 million to sales and marketing expenses and a decrease in general and administrative
expenses for the same amount for the year ended December 31, 2019. As a result, the reclassifications had no effect on net earnings,
retained earnings or cash flows as previously reported.
Use of Estimates
Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most
significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the
expected net collectable value of its accounts receivable and related revenue, inventory reserves, the life of its leased and sales demo unit
devices, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.
Fair Value of Financial Instruments
The Company’s financial instruments include cash, accounts receivable, accounts payable, and accrued liabilities, for which current
carrying amounts approximate fair value due to their short-term nature.
Cash
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Short-term investments include investments with maturities greater than three months, but not exceeding 12 months, or highly liquid
investments with maturities greater than 12 months that the Company intends to liquidate during the next 12 months for working capital
needs.
Accounts Receivable, Net
The Company’s accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the
Company’s devices, related supplies or complimentary products. In conjunction with fulfilling the Company’s obligation to deliver a
product, the Company bills the patient’s third-party payor or the patient. Billing adjustments represent the difference between the list
prices and the reimbursement rates set by third-party payors, including Medicare, commercial payors and amounts billed directly to the
patient. Specific amounts, if uncollected over a period of time, may be written off after several appeals, which in some cases may take
longer than twelve months. Primarily all of the Company’s receivables are due from patients with commercial or government health
plans and workers compensation claims with a small portion related to private pay individuals, attorney and auto claims.
F-8
Table of Contents
Inventory, Net
Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard costs, which approximates actual
costs on an average cost basis. Following are the components of inventory as of December 31, 2020 and 2019:
Raw Materials
Work-in-process
Finished Goods
Less: reserve
December 31, 2020 December 31, 2019
$
$
$
3,213
1,455
4,119
8,787
(152)
8,635
$
$
$
953
200
1,640
2,793
(415)
2,378
The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate.
The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on
hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently
projected by management, additional inventory write-downs may be required.
Property and Equipment
Property and equipment is recorded at cost. Repairs and maintenance expenditures are charged to expense as incurred. We compute
depreciation expense on a straight-line basis over the estimated useful lives of the assets as follows:
Classification
Office furniture and equipment
Assembly equipment
Vehicles
Leasehold improvements
Leased devices
Leases
Estimated Useful Life
5 to 7 years
7 years
5 years
Term of lease
9 months
The Company determines if an arrangement is a lease at inception or modification of a contract.
The Company recognizes finance and operating lease right-of-use assets and liabilities at the lease commencement date based on the
estimated present value of the remaining lease payments over the lease term. For our finance leases, the Company uses the implicit rate
to determine the present value of future lease payments. For our operating leases that do not provide an implicit rate, the Company uses
incremental borrowing rates to determine the present value of future lease payments. The Company includes options to extend or
terminate a lease in the lease term when it is reasonably certain to exercise such options. The Company recognizes leases with an initial
term of 12 months or less as lease expense over the lease term and those leases are not recorded on our Consolidated Balance Sheets.
For additional information on our leases where the Company is the lessee, see Note 9- Leases.
A significant portion of our device revenue is derived from patients who obtain our devices under month-to-month lease arrangements
where the Company is the lessor. Revenue related to devices on lease is recognized in accordance with ASC 842, Leases. Using the
guidance in ASC 842, we concluded our transactions should be accounted for as operating leases based on the following criteria below:
● The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.
● The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to
exercise.
F-9
Table of Contents
● The lease term is month to month, which does not meet the major part of the remaining economic life of the underlying
asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion
shall not be used for purposes of classifying the lease.
● There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed
substantially all of the fair value of the underlying asset
● The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.
Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices
are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at
any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.
Revenue Recognition
Revenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The
Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration
to which the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is
delivered to the patient, which is when control is deemed to have transferred to our patient.
Sales of our devices and supplies are primarily made with, and shipped directly to the patient with a small amount of revenue generated
from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for
purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients
covered by third-party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue
recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have
any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the
patient. There are no substantial costs incurred through support or warranty obligations.
The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases
subject to ASC 842 (in thousands):
Device revenue
Purchased
Leased
Total Device revenue
For the Years Ended December 31,
2020
2019
$
$
6,390
14,879
21,269
$
$
4,035
6,678
10,713
Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of
receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-
party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these
estimates is the risk that they will have to be revised as additional information becomes available and constraints are released.
Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products
from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts
originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our
forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any
differences between estimated and actual collectability are reflected in the period in which received. Historically these differences have
been immaterial and the Company has not had a significant reversal of revenue from prior periods.
A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or
practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain
timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net
revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible
F-10
Table of Contents
amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue
to fluctuate significantly from quarter to quarter and year to year.
Stock-based Compensation
The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an
award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during
the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide
service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For
awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable
that the performance conditions will be achieved.
Earnings Per Share
We calculate basic earnings per share on the basis of the weighted-average number of shares of common stock outstanding during the
period. Diluted earnings per share is calculated using the weighted-average number of shares of common stock outstanding for the
period plus the effect of potential dilutive common shares during the period using the treasury stock method. Potential shares of common
stock outstanding include unvested restricted stock awards, vested and unvested unexercised stock options and common stock purchase
warrants.
Research and Development
Research and development costs are expensed when incurred. Research and development expense for the years ended December 31,
2020 and 2019 was approximately $0.8 million and $0.6 million, respectively. Research and development, which includes salaries related
to research and development and raw materials, are included in general and administrative expenses on the consolidated statement of
comprehensive income.
Income Taxes
We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets
and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as any operating loss and tax credit carry-
forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in
which those temporary differences are expected to be recovered or settled. We reduce deferred tax assets by a valuation allowance if,
based on available evidence, it is more likely than not that these benefits will not be realized.
We recognize tax benefits from uncertain tax positions if it is more likely than not that the tax position will be sustained on examination
by the taxing authorities based on the technical merits of the position.
Recently Issued Accounting Pronouncements
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit
Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and
certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach
with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required
to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also
simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods
beginning after December 15, 2022, and interim periods therein for smaller reporting companies. Early adoption is permitted for annual
periods beginning after December 15, 2018, and interim periods therein. The Corporation is currently evaluating the impact that the
adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.
Management has evaluated other recently issued accounting pronouncements and does not believe that this pronouncement will have a
material impact on the Company’s consolidated financial statements.
F-11
Table of Contents
(3) PROPERTY AND EQUIPMENT
The components of property and equipment are as follows (in thousands):
Property and equipment
Office furniture and equipment
Assembly equipment
Vehicles
Leasehold improvements
Sales Rep demo units
Leased devices
Less accumulated depreciation
December 31, 2020 December 31, 2019
$
$
$
2,362
143
198
559
361
809
4,432
(2,507)
1,925
$
$
$
1,178
128
181
500
—
934
2,921
(2,063)
858
The Company monitors devices out on lease for potential loss and places an estimated reserve on the net book value based on an analysis
of the number of units of which are still with patients for which the Company cannot determine the current status.
Total depreciation expense related to our purchased property and equipment was $0.7 million and $0.3 million for the years ended
December 31, 2020 and 2019, respectively.
Total depreciation expense related to devices out on lease was $0.8 million and $0.5 million for the years ended December 31, 2020 and
2019, respectively. Depreciation on leased units is reflected on the income statement as cost of revenue.
During the year ended December 31, 2020, the Company began capitalizing product demo units sent to its territory managers to use in
the field. The Company monitors these devices for potential losses and places an estimated reserve on the net book value based on an
analysis of terminated territory managers that have not yet returned their units.
Total depreciation expense related to demo unit devices out with sales rep was $0.2 million for the year ended December 31, 2020.
Deprecation on demo units is reflected on the income statement as sales and marketing expense.
(4) EARNINGS PER SHARE
The calculation of basic and diluted earnings per share for the years ended December 31, 2020 and 2019 are as follows:
Basic earnings per share
Net income available to common stockholders
Basic weighted-average shares outstanding
Basic earnings per share
Diluted earnings per share
Net income available to common stockholders
Weighted-average shares outstanding
Effect of dilutive securities - options and restricted stock
Diluted weighted-average shares outstanding
Diluted earnings per share
For the Years Ended December 31,
2020
2019
$
$
$
$
$
$
$
9,074
33,869
0.27
9,074
33,869
1,074
34,943
9,492
32,439
0.29
9,492
32,439
1,524
33,963
0.26
$
0.28
For the years ended December 31, 2020 and 2019, 0.2 million and 0.3 million shares of common stock were excluded from the dilutive
stock calculation because their effect would have been anti-dilutive.
F-12
Table of Contents
(5) STOCK-BASED COMPENSATION PLANS
Zynex, Inc. 2017 Stock Incentive Plan
The Company currently has one active long-term incentive plan. The Company’s 2017 Stock Incentive Plan (the “2017 Stock Plan”) is
the Company’s equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals
providing services to the Company. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. The 2017
Stock Plan mandates a maximum award term of 10 years and stipulates that stock options be granted with prices not less than fair market
value on the date of grant. Stock option awards generally vest over four years. Restricted stock awards typically vest quarterly over three
years for grants issued to members of our Board of Directors and quarterly or annually over two to four years for grants issued to
employees. For stock option awards, all awards granted under the 2017 Stock Plan are stock-settled with common stock issued upon
exercise. For restricted stock awards, shares are issued to the recipient upon grant with a restrictive legend and are not included in the
calculation of outstanding shares until vesting occurs. At December 31, 2020, there were 3.6 million shares available for future grants
under the 2017 Stock Plan.
The 2005 Stock Plan expired as of December 31, 2014. Vesting provisions of the expired plan were to be determined by the Board of
Directors. All stock options under the 2005 Stock Plan expire no later than ten years from the date of grant. Options granted in 2015,
2016 and through May 2017 prior to the approval of the 2017 Stock Incentive Plan were approved and certified by the board of directors
on September 6, 2017 under the existing 2005 stock option plan.
As of December 31, 2020, the Company had 1.0 million stock options outstanding and 0.6 million stock options exercisable under the
following plans:
Plan Category
2005 Stock Option Plan
Equity Compensation Plans not approved by Shareholders
2017 Stock Option Plan
Total
Outstanding Number of Options Exercisable Number of Options
(in thousands)
(in thousands)
299
37
670
1,006
$
299
25
251
575
The Company estimates the grant-date fair value of stock option awards using the Black-Scholes option pricing model and restricted
stock awards at intrinsic value on the date of grant. The following assumptions were used in estimating the grant date fair value of stock
options granted during the years ended December 31, 2020 and 2019:
Weighted average expected term
Weighted average volatility
Weighted average risk-free interest rate
Dividend yield
2020
6.79 years
2019
6.25 years
117 %
1.59 %
0 %
122 %
2.30 %
0 %
The weighted average expected term of stock options represents the period of time that the stock options granted are expected to be
outstanding based on historical exercise trends. The weighted average expected volatility is based on the historical price volatility of the
Company’s common stock. The weighted average risk-free interest rate represents the U.S. Treasury bill rate for the expected term of the
related stock options. The dividend yield represents the Company’s anticipated cash dividend over the expected term of the stock options.
Forfeitures are accounted for as they occur.
F-13
Table of Contents
The following table summarizes stock-based compensation expenses recorded in the condensed consolidated statements of operations (in
thousands):
Cost of Revenue
Sales and marketing expense
General, and administrative
Total stock based compensation expense
For the Years Ended December 31,
2020
2019
$
$
37
424
2,220
2,681
21
205
594
820
The excess tax benefit associated with our stock-based compensation plans for the years ended December 31, 2020 and 2019, was
approximately $1.7 million and $0.8 million, respectively.
A combined summary of stock option activity for all plans for the years ended December 31, 2020 and 2019 is presented below:
Number of
Shares
(in thousands)
Weighted
Average
Strike
Price
Weighted
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
(in thousands)
Outstanding at December 31, 2018
Granted
Exercised
Expired
Forfeited
Outstanding at December 31, 2019
Outstanding at December 31, 2019
Granted
Exercised
Forfeited
Outstanding at December 31, 2020
$
1,885
$
653
(503) $
(6) $
(174) $
$
1,855
$
1,855
$
14
(622) $
(241) $
$
1,006
0.80
5.81
0.44
1.00
2.64
2.48
2.48
10.15
0.90
4.68
3.04
Exercisable at December 31, 2020
575
$
1.62
6.42
$
10,032
6.47
5.35
$
$
10,483
6,807
Range
$0 to $2.00
$2.01 to $4.00
$4.01 to $6.00
$6.01 to $8.00
$8.01 to $10.00
$10.01 to $12.00
Outstanding Weighted average
Number of
Options
(in thousands)
Remaining
Contractual
Life (years)
Weighted Average Exercisable Number of
Remaining Exercisable
Strike Price
Options (in thousands) Contractual Life (years)
Weighted Average
Exercisable
Strike Price
473
270
19
200
41
3
1,006
4.60
7.66
8.25
8.56
8.92
9.04
6.47
$
$
$
$
$
$
$
0.35
3.05
4.45
7.87
9.22
10.60
3.04
F-14
401
116
—
50
8
—
575
4.28
7.43
$
$
— $
8.56
8.86
$
$
— $
5.35
$
0.33
2.87
—
7.87
8.98
—
1.62
Table of Contents
A summary of our unvested stock options as of December 31, 2020 and 2019 and related activity is presented below:
Non-vested at December 31, 2018
Granted
Vested
Forfeited
Non-vested at December 31, 2019
Non-vested at December 31, 2019
Granted
Vested
Forfeited
Non-vested at December 31, 2020
Non-vested
Shares
Under
Option
Weighted
Average
Grant Date
(in thousands) Fair Value
1.44
5.12
1.24
2.44
4.03
4.03
8.88
3.34
4.36
4.35
$
569
653
$
(169) $
(163) $
$
890
$
890
14
$
(251) $
(222) $
$
431
A summary of restricted stock award activity under the 2017 Stock Plan for the years ended December 2020 and 2019 are presented
below:
Number of Shares Weighted Average
Outstanding at December 31, 2018
Granted
Vested
Outstanding at December 31, 2019
Outstanding at December 31, 2019
Granted
Vested
Outstanding at December 31, 2020
(in thousands)
Grant Date Fair Value
3.19
8.10
3.24
5.81
$
76
55
$
(29) $
$
102
$
102
$
320
(154) $
$
268
5.81
12.92
8.54
12.64
As of December 31, 2020, there was approximately $4.3 million of total unrecognized compensation costs related to unvested stock
options and restricted stock. These costs are expected to be recognized over a weighted average period of 2.3 years.
The total intrinsic value of stock option exercises for the years ended December 31, 2020 and 2019 was $9.6 million and $4.4 million,
respectively. The total fair value of restricted stock awards vested during the years ended December 31, 2020 and 2019 was $1.3 million
and $0.1 million, respectively.
(6) STOCKHOLDERS’ EQUITY
Equity Offering
On July 17, 2020, the Company completed an underwritten public offering of an aggregate 2.5 million shares of common stock at a
public offering price of $22.00 per common share. In the offering, 1.25 million shares of common stock were sold by the Company and
1.25 million shares of common stock were sold by Sandgaard Holdings, LLC, which is 100% controlled by Thomas Sandgaard, CEO
and Chairman of the Board of Directors. Net proceeds to the Company, after deducting for direct costs associated with the offering, were
$25.2 million.
Common Stock Dividend
The Company’s Board of Directors declared a cash dividend of $0.07 per share on November 6, 2018. The dividend of $2.3 million was
paid on January 18, 2019 to stockholders of record as of January 2, 2019.
F-15
Table of Contents
Any determination to declare a future quarterly dividend, as well as the amount of any cash dividend which may be declared, will be
based on our financial position, earnings, earnings outlook and other relevant factors at that time.
Treasury Stock
From December 6, 2017 through March 6, 2018, we had the ability through our stock purchase program to re-purchase our common
stock at prevailing market prices either in the open market or through privately negotiated transactions up to $2.0 million. On March 6,
2018, we reached the limit of $2.0 million and share re-purchases were ceased. From the inception of the plan through March 6, 2018,
we purchased 495,091 shares of our common stock for $2.0 million or an average price of $4.04 per share.
From May 14, 2018 through May 13, 2019, we had the ability through our stock repurchase program to re-purchase our common stock at
prevailing market rates either in the open market or through privately negotiated transactions up to $2.0 million. From the inception of
the plan through May 13, 2019, the Company purchased 576,129 shares of our common stock for $1.8 million or an average price of
$3.20 per share. As of December 31, 2020 the Company had no outstanding stock repurchase programs.
Warrants
A summary of stock warrant activity for the years ended December 31, 2020 and 2019 are presented below:
Weighted
Average
Exercise
Weighted
Average
Remaining
Contractual
Aggregate
Intrinsic
Value
Number of
Warrants
Outstanding at December 31, 2018
Granted
Exercised
Forfeited(1)
Outstanding and Exercisable at December 31, 2019
Outstanding at December 31, 2019
Granted
Exercised
Forfeited
Outstanding and Exercisable at December 31, 2020
Life (Years) (in thousands)
79
5.77 $
(in thousands) Price
150
$ 2.42
— $ —
(40) $ 2.00
(10) $ 2.00
$ 2.63
100
$ 2.63
100
— $ —
— $ —
— $ —
$ 2.63
100
4.77
4.77
$
$
525
525
3.76
$
1,084
(1) Warrants were exercised under a net exercise provision in the warrant agreement. As a result, approximately 10,000 warrants were
forfeited in lieu of cash payment for shares.
(7) INCOME TAXES
The pre-tax income from continuing operations on which the provision for income taxes was computed is as follows (in thousands):
United States
Foreign
Total
2020
$ 10,185
(32)
10,153
2019
$ 11,964
(23)
11,941
F-16
Table of Contents
Income tax expense consists of the following for the years ended December 31, 2020 and 2019 (in thousands):
Current tax expense:
Federal
State
Total tax expense:
Deferred tax expense/(benefit):
Federal
State
Total deferred tax expense/(benefit):
Total
2020
2019
$
$
$
$
841
292
1,133
(122)
68
(54) $
$
1,079
1,865
372
2,237
120
92
212
2,449
A reconciliation of income tax computed at the U.S. statutory rate of 21% to the effective income tax rate is as follows:
Statutory rate
State taxes
Permanent differences and other
Change in valuation allowance
Stock based compensation
Other (true – up)
Effective rate
2020
2019
21 %
3
1
—
(15)
—
10 %
21 %
3
—
(1)
(4)
1
20 %
The tax effects of temporary differences that give rise to deferred tax assets (liabilities) at December 31, 2020 and 2019 are as follows (in
thousands):
Deferred tax assets:
Accrued expenses
Lease liability
Accounts receivable
Inventory
Stock based compensation
Tax Credits and NOL Carryforward
Other
Amortization
Less: Valuation allowance
Deferred tax assets
Deferred tax Liabilities:
Property and equipment
Finance lease
Right-of-use asset
Prepaid Expenses
Deferred tax liabilities
Net Deferred tax assets
2020
2019
$
$
$
$
$
$
10
1,721
18
495
306
20
1
43
2,614
—
$
2,614
(470)
(78)
(1,480)
(20)
(2,048)
566
$
$
$
34
1,109
19
232
145
110
1
50
1,700
—
1,700
(192)
(45)
(946)
(4)
(1,187)
513
As of December 31, 2020, the Company has net operating loss carryforwards in various states of approximately $0.5 million, which
expire at various dates ranging from five to seven years.
F-17
Table of Contents
In addition, the Company had no recorded valuation allowances at December 31, 2020 and 2019.
The accounting standard related to income taxes applies to all tax positions and defines the confidence level that a tax position must meet
in order to be recognized in the financial statements. The accounting standard requires that the tax effects of a position be recognized
only if it is "more-likely-than-not" to be sustained by the taxing authority as of the reporting date. If a tax position is not considered
"more-likely-than-not" to be sustained, then no benefits of the position are to be recognized. Differences between financial and tax
reporting which do not meet this threshold are required to be recorded as unrecognized tax benefits. This standard also provides guidance
on the presentation of tax matters and the recognition of potential IRS interest and penalties. As of December 31, 2020 and 2019, the
Company does not have an unrecognized tax liability.
The Company does not classify penalty and interest expense related to income tax liabilities as an income tax expense. Penalties and
interest are included within general and administrative expenses on the consolidated statements of operations.
The Company files income tax returns in the U.S. and various state jurisdictions, and there are open statutes of limitations for taxing
authorities to audit our tax returns from 2015 through the current period.
(8) DEFERRED INSURANCE REIMBURSEMENT
During the first quarter of 2016, the Company collected $880,000 from a single insurance company for accounts receivable. The
accounts receivable had been previously reduced to zero by the allowance for billing adjustments. Subsequent to March 31, 2016, the
insurance company verbally communicated to the Company that this payment was made in error and requested it be refunded to the
insurance company. The Company recorded this $880,000 insurance reimbursement as a deferred insurance liability.
During the first quarter of 2019, the Company recognized $880,000 as other income and reversed the liability as management’s
assessment was that any repayment obligation was deemed remote. The Company has included this amount in other income in order to
ensure comparability of the Company’s operating income results for the years ended December 31, 2019 and 2018. Management’s legal
determination that any refund obligation is remote was based on the facts and circumstances related to the dispute, which included
reviewing the legal statutes within the jurisdictions the Company operates.
(9) LEASES
The Company has four operating leases pertaining to its corporate headquarters located in Colorado. Details of each lease are as follows:
● The Company entered into a sublease agreement on October 20, 2017 with CSG Systems Inc. for approximately 41,715 square
feet. The term of the sublease runs through June 30, 2023, with an option to extend for an additional two years through June
30, 2025. During the first year of the sublease, the rent per square foot was $7.50, which increased to $19.75 during the second
year of the sublease. Each year thereafter increasing by an additional $1 per square foot. The Company has not yet determined
whether it is reasonably certain to exercise its renewal option and has therefore only considered the initial term in the
calculation of the lease liability and lease asset. The Company is also obligated to pay its proportionate share of building
operating expenses. The sub-landlord agreed to contribute approximately $0.2 million toward tenant improvements which was
accounted for as a reduction of the operating lease asset and subsequently treated as a reduction of rent expense over the term of
the lease. Upon lease commencement, the Company recorded an operating lease liability of $3.9 million and a corresponding
right-of-use asset for $3.6 million. The remaining lease term was 2.8 years at December 31, 2020.
● The Company entered into an amendment to its sublease agreement, above, on March 11, 2019 for an additional 21,420 square
feet of office space. The term of the sublease for the additional space began on June 1, 2019 and runs through June 30, 2023,
with an option to extend the term for an additional two years through June 30, 2025. During the first seven months of the
Amendment to the Sublease, the rent per square foot was $10.00, which increased to $20.75 from January 1, 2020 through
October 31, 2020. For annual periods beginning November 1, 2020, the price per square foot increases by an additional $1 per
square foot. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use
asset for $1.6 million each. The remaining lease term was 2.8 years at December 31, 2020.
F-18
Table of Contents
● The Company entered into an amendment to its sublease agreement, above, on January 3, 2020, for an additional 22,546 square
feet of office space. The term of the sublease began on March 9, 2020 and will run through June 30, 2025. From the
commencement date through October 31, 2020, the rent per square foot is $13.00, increasing to $21.75 per square foot from
November 1, 2020 through October 31, 2021. The price per square foot increases by an additional $1 annually beginning
November 1, 2021. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-
of-use asset for $1.4 million each. The remaining lease term was 2.8 years at December 31, 2020.
● The Company entered into a lease agreement on September 17, 2020 with GIG CW Compark, LLC for approximately 50,488
square feet. The term of the lease is 65 months, which begins on January 5, 2021. The lease includes an option to extend the
lease for one additional five year period. Base rent begins at $9.40 per square feet increasing each year thereafter by an
additional $0.30 per square foot. The Company has not yet determined whether or not it is reasonably certain to exercise its
renewal option. The Company is also obligated to pay its proportional share of building operating expenses. The landlord
agreed to contribute approximately $0.4 million toward tenant improvements. The Company determined that lease
commencement occurred earlier than lease inception on January 5, 2021 as the Company began making significant tenant
improvements and storing inventory at this location during December 2020. As a result, the Company recorded an operating
lease liability of $2.4 million and a corresponding right-of-use asset of $2.1 million as of December 31, 2020. The remaining
lease term was 5.4 years at December 31, 2020. The Company has three finance leases for office equipment as follows:
● The Company entered into an equipment lease on September 20, 2019 with Konica Minolta Premier Finance for a
copier/printer and related software located at its corporate offices. The term of the equipment lease agreement is 5 years with
the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase
the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability.
Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the
Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease
term was 3.8 years at December 31, 2020.
● The Company entered into an equipment lease on March 3, 2020 with Konica Minolta Premier Finance for copiers/printers and
related software located at its corporate offices. The term of the equipment lease agreement is 4 years with the option to
purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment
and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid
monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a
finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 3.2 years at
December 31, 2020.
● The Company entered into an equipment lease on November 25, 2020 with Konica Minolta Premier Finance for
copiers/printers and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease
is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the
option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease
asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease
commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each.
The remaining lease term was 4.9 years at December 31, 2020.
The Company’s operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the
discount rate when measuring lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company
would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease.
The Company’s incremental borrowing rate was determined to be 4.0% for its operating lease liabilities. The Company’s equipment
lease agreements have implicit rates from 8.3% to 9.7%, which was used to measure its finance lease liability.
F-19
Table of Contents
The table below reconciles the undiscounted future minimum lease payments under the Company’s operating and finance leases to the
total operating and capital lease liabilities recognized on the consolidated balance sheets as of December 31, 2019 (in thousands):
2021
2022
2023
2024
2025
2026
Total undiscounted future minimum lease payments
Less: Difference between undiscounted lease payments and discounted lease liabilities:
Total lease liabilities
Operating lease liability Finance lease liability
105
105
105
77
35
—
427
(67)
360
2,352
2,447
1,514
512
528
223
7,576 $
(605)
6,971
$
$
$
Operating and finance lease costs were $6.6 million and $1.2 million for years ended December 31, 2020 and 2019, which were included
in the consolidated statement of operations under the following headings (in thousands):
Operating Lease expense
Costs of revenue - devices and supplies
Sales and marketing expense
General and administrative
Total operating lease expense
Finance Lease expense
Amortization of right-of-use asset:
Costs of revenue - devices and supplies
Sales and marketing expense
General and administrative
Total amortization of right-of-use asset
Interest expense and other
Total finance lease expense
For the years ended December 31,
2020
2019
$
$
$
$
740
1,783
3,993
6,516
7
18
36
61
20
81
$
$
$
$
121
170
859
1,150
2
4
13
19
5
24
(10) COMMITMENTS AND CONTINGENCIES
See Note 9 for details regarding commitments under the Company’s long-term leases.
From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that
such claims and litigation arise, management provides for them if losses are determined to be both probable and estimable.
The Company is currently not a party to any material pending legal proceedings.
(11) CONCENTRATIONS
The Company is exposed to concentration of credit risk related primarily to its cash balances. The Company maintains its cash balances
in major financial institutions that exceed amounts insured by the FDIC (up to $250,000, per financial institution as of December 31,
2020). The Company has not experienced any realized losses in such accounts and believes it is not exposed to any significant credit risk
related to its cash.
The Company had one major vendor from which is sourced approximately 22% and 49%, respectively, of supplies for its electrotherapy
products for the years ended December 31, 2020 and 2019. Management believes that its relationships with its suppliers are good. If the
relationships were to be replaced, there may be a short-term disruption for a period of time in which products may not be available and
additional expenses may be incurred as the Company locates additional or replacement suppliers.
F-20
Table of Contents
The Company had receivables from one third-party payor at December 31, 2020 which made up approximately 26% of the accounts
receivable balance. The Company had receivables from two third-party payors at December 31, 2019, which made up approximately
39% of the accounts receivable balance.
(12) RETIREMENT PLAN
In 2012, the Company established a defined contribution retirement plan for its employees under section 401(k) of the Internal Revenue
Code (the “401(k) Plan”) that is available to all employees 18 years of age or older with three months of service. All employee
contributions are fully vested immediately and employer contributions vest over a period of four years. The Company has a
discretionary employee match program and currently matches 35% of first 6% of an employee’s contributions.
During the years ended December 31, 2020 and 2019, The Company recorded an expense of $0.3 million and $0.1 million, respectively,
under the aforementioned plan, related to the Company match.
(13) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
Quarterly financial information is as follows (in thousands, except per share data):
Total Revenue
Less: cost of revenue and
operating expenses
Income from operations
Income before income taxes
Net income
Net income per common share:
Basic income per share - net
income
Diluted income per share - net
income
$
$
$
Total Revenue
Less: cost of revenue and
operating expenses
Income from operations
Income before income taxes
Net income
Net income per common share:
Basic income per share - net
income
Diluted income per share - net
income
$
$
$
First Quarter Second Quarter Third Quarter Fourth Quarter
2019
$
9,196
$
10,297
$
11,817
$
14,162
6,940
2,256
3,136
7,713
2,584
2,584
9,322
2,495
2,496
2,350
$
2,162
$
2,033
$
0.07
0.07
$
$
0.07
0.06
$
$
0.06
0.06
$
$
10,431
3,731
3,725
2,947
0.09
0.09
2020
First Quarter Second Quarter Third Quarter Fourth Quarter
$
15,228
$
19,263
$
20,026
$
25,605
12,770
15,178
18,617
23,308
2,458
2,454
4,085
4,080
1,409
1,404
2,937
$
3,017
$
1,333
$
0.09
0.09
$
$
0.09
0.09
$
$
0.04
0.04
$
$
2,297
2,215
1,787
0.05
0.04
F-21
Table of Contents
(14) COVID-19
In December 2019, a novel Coronavirus disease (“COVID-19”) was reported and on March 11, 2020, the World Health Organization
characterized COVID-19 as a pandemic. During the second and third quarters, the Company’s operations were impacted by closures of
clinics and reductions in elective surgeries which decreased availability of physicians to prescribe our products. Additionally, the
Company had to navigate the impacts it had on employee and supply chain issues. While the Company did not see a significant impact
on its operating results or financial position during the year ended December 31, 2020 from COVID-19, it is unable at this time to predict
the impact that COVID-19 will have on its business, financial position and operating results in future periods due to numerous
uncertainties. The Company has been and continues to closely monitor the impact of the pandemic on all aspects of its business.
F-22
DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
Exhibit 4.2
Zynex Inc. (“Zynex” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”).
DESCRIPTION OF COMMON STOCK
The authorized capital stock of the Company consists of 100,000,000 shares of common stock at a par value of $0.001 per share and
10,000,000 shares of preferred stock at par value of $0.001 per share.
Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters to be voted on by the
stockholders. Holders of common stock are entitled to receive dividends ratably, when, as and if declared by the board of directors, out of
funds legally available. In the event of liquidation, dissolution or winding-up the holders of common stock are entitled to share equally
and ratably in all assets remaining available for distribution after payment of liabilities and after provision is made for each class
of stock, if any, having preference over the common stock. Holders of common stock have no conversion, preemptive, or other
subscription rights and there are no redemption provisions applicable to the common stock.
Name
Zynex Medical, Inc.
Zynex Monitoring Solutions, Inc.
Zynex NeuroDiagnostics, Inc.
Zynex Europe, ApS
Pharmazy, Inc
SUBSIDIARIES OF ZYNEX, INC.
Jurisdiction
Colorado
Colorado
Colorado
Denmark
Colorado
Exhibit 21
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Zynex Inc.’s Registration Statements on Form S-3 (File Nos. 333-230128 and 333-
232267) and on Form S-8 (File No. 333-220366) of our report dated February 25, 2021, relating to the December 31, 2020 consolidated
financial statements which appears in Zynex, Inc.’s Form 10-K for the year ended December 31, 2020.
Exhibit 23.1
February 25, 2021
Denver, CO
/s/ Plante & Moran PLLC
Exhibit 31.1
I, Thomas Sandgaard, certify that:
1. I have reviewed this annual report on Form 10-K of Zynex, Inc.;
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Dated: February 25, 2021
/s/ THOMAS SANDGAARD
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive
Officer
Exhibit 31.2
I, Daniel Moorhead, certify that:
1. I have reviewed this annual report on Form 10-K of Zynex, Inc.;
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Dated: February 25, 2021
/s/ DANIEL MOORHEAD
Daniel Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
Each of the undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his
knowledge:
1. This Annual Report on Form 10-K for the year ended December 31, 2020 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of
operations of Zynex for the period covered by this Report.
This Certification is executed as of February 25, 2021
/s/ THOMAS SANDGAARD
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
Each of the undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his
knowledge:
1. This Annual Report on Form 10-K for the year ended December 31, 2020 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of
operations of Zynex for the period covered by this Report.
This Certification is executed as of February 25, 2021.
/s/ DANIEL MOORHEAD
Daniel Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer